

**TENDER FOR ENTERING INTO A RATE CONTRACT FOR SUPPLY OF DRUGS,  
FOR AIIMS, BILASPUR**

**TENDER DOCUMENT**

<b>Tender document download starts on</b>	25/01/2023
<b>Pre Bid meeting</b>	01/02/2023
<b>Commencement of online submission</b>	14/02/2023
<b>Last date and time for online submission</b>	08/03/2023
<b>Tender (Technical Bids ) opening on</b>	13/03/2023
<b>Cost of the Tender Processing Fee</b>	Rs.600
<b>Cost of EMD</b>	Rs. 2,00,000/-

**Telephone No. 8285336995, 8894867079**

**Email: [storeofficer@aiimsbilaspur.edu.in](mailto:storeofficer@aiimsbilaspur.edu.in)**

**CONTENTS**

S. No.	Description	Page No.
1	Notice Inviting Tender	3
2	Tender Timelines	4
3	Bill of Quantity/List of Drugs with Estimated Annual Requirements	5 -22
4	Terms & Conditions of E-Tender	23
5	Eligibility Conditions for Bidders	23
6	Eligibility Criteria for selecting Renal Transplant Drugs	25
7	Purchase Preference	26
8	Performance Security Deposit (PSD)	27
9	Techno-Commercial Bid	29
10	Price Bid	30
11	Earnest Money Deposit (EMD)	31
12	Tender Validity	32
13	Scrutiny and Evaluation of Tenders	33
14	General Conditions of Contract	35
15	Special Conditions	37
16	Samples	39
17	Supply Conditions	39
18	Delivery Conditions	41
19	Packaging	42
20	Other Conditions	42
21	Quality	43
22	Penalty	44
23	Force Majeure	44
24	Blacklisting	45
25	Requirement of Godown Space	45
26	Points to Remember	46
27	Liquidated Damage/Risk/Termination Clause	46
28	Jurisdiction of Court	47
29	Tender Form (Annexure 1)	48
30	Declaration of the bidder (Annexure 2)	49
31	Affidavit (Annexure 3)	50
32	Appendix -A Self-certification format for claiming purchase preference under the “Public Procurement preference to Make in India” order	51
33	GFR-144 (xi) compliance certificate (Annexure 4)	54
34	Manufacturer's Authorization form (Annexure 5)	55
34	Check List (Annexure 6)	56

No.

Dated:

---

**NOTICE INVITING TENDER (NIT)**

Sub: Tender for Entering into a Rate Contract for the Supply of Drugs, for the period of 2 years

\*\*\*\*\*

Tenders are invited from eligible and qualified bidders for entering into a rate contract for the supply of the Drugs For 2 years

- |                              |  |
|------------------------------|--|
| 1. Scope of work:            | Rate contract for supply of Drugs  |
| 2. Value of tender:          | Rs. 30 crores for 2 years(Estimated)   |
| 3. Duration of the contract: | Two years and extendable up to one year or finalization of tender whichever is earlier |

(Rates quoted should be valid for Two Years)

4. Address for Communication: Store Section, Block D, Basement-1, AIIMS, Bilaspur, Himachal Pradesh
5. Contact official: Dr. Mohammad Kausar, Faculty In charge (Procurement)
6. Phone Number: **8285336995, 9910499690**

**7. TENDER TIMELINES:**

- i. Date from which tender documents can be downloaded:
- ii. Last date for receipt of pre-bid queries:
- iii. Pre-bid meeting date, time and venue :
- iv. Purchase section:
- v. Date and time of start of Bid submission :
- vi. Closing date & time for submission of online bids :
- vii. Time and date of online opening of Technical Bids:
- viii. Time and date of online opening of Price Bids:

8. **Earnest Money Deposit: Rs. 2,00,000/-** and Tender Processing fee: **Rs. 600/-** (Inclusive of 18% GST) to be paid through account payee Demand draft, FDR, Bankers cheque Bank guarantee, DD. The EMD shall be returned without interest to the non-successful tenderers after acceptance of award of contract by the successful bidder. Tender Processing fee will not be refunded under any circumstance.

9. Interested bidders are advised to download the complete Tender Enquiry document from the websites **<https://eprocure.gov.in/eprocure/app> or Store Section, Block D, AIIMS, Bilaspur (HP) for complete details.**

10. Pre-bid queries can be made before pre-bid meeting through e-mail **[msofficeaiimsbls@gmail.com](mailto:msofficeaiimsbls@gmail.com)** up to the time mentioned above under clause 7(ii) of this NIT.

11. The prospective bidders must register with the E-procurement system of <https://eprocure.gov.in/eprocure/app>. Special Instructions to the bidders for the e- submission of the bids online through this e-Procurement Portal on completion of the registration process is given in <https://eprocure.gov.in/eprocure/app>. The bidders will be provided user ID and password upon enrolment. In order to submit the bids electronically, bidders are required to have a valid Class 3 Digital Signature Certificate (signing and encryption/ decryption certificates).

12. Bidders are requested to read the bidders help document on e-tender web site before proceeding for bidding.

13. Post receipt of User ID & Password, bidders can log on for downloading & uploading tender document.

14. The bidders shall submit the required fee (as per tender conditions clause 8) through SBI collect only before the due date and time mentioned above. Fee payment receipts must be submitted in hard copies in store section, AIIMS, Bilaspur (HP).

15. Prospective bidders are advised to browse the above mentioned websites (i.e.) <https://eprocure.gov.in/eprocure/app> regularly before submission of their bids, as any further amendments, addendums or corrigenda will be published in these websites only.

**LIST OF DRUGS FOR HOSPITAL FORMULARY (list for one year X 3)**  
**(Quantity of drugs may be increased in subsequent years)**

S. NO.	NOMENCLATURE	APPROXIMATE ANNUAL REQUIREMENT IN UNITS	RATE SHOULD BE QUOTED FOR EACH UNIT
<b>ORAL DRUGS (TABLETS &amp; CAPSULES)</b>			
Supply in loose packing will not be accepted. Wherever metallic foil pack is mentioned, supply should be made in metallic foil pack on both sides failing which the supply may be rejected. All items should conform strictly to IP/BP/USP standards unless otherwise mentioned.			
1.	Acetazolamide 250 mg	1200	Tab
2.	Acetylsalicylic acid 150 mg	30000	Tab
3.	Acetylsalicylic acid 75 mg	100	Tab
4.	Activated charcoal 500 mg	1000	Tab/Sachet
5.	Acyclovir 200 mg	13500	Tab
6.	Albendazole 400 mg	12000	Tab
7.	Allopurinol 100 mg	3000	Tab
8.	Alprazolam 0.5 mg	600	Tab
9.	Amiodarone 100 mg	1000	Tab
10.	Amitriptyline 10 mg	3500	Tab
11.	Amitriptyline 25 mg	12500	Tab
12.	Amlodipine 2.5 mg	600	Tab
13.	Amlodipine besylate 5 mg	17000	Tab
14.	Amoxicillin 250 mg	2000	Cap
15.	Amoxicillin 500 mg	28000	Cap
16.	Amoxicillin 250 mg + Clavulanic acid 125 mg	3000	Tab
17.	Amoxicillin 500 mg + Clavulanic acid 125 mg	72000	Tab
18.	Arginine 1000 mg	20	Cap
19.	Artemether 20 mg + Lumefantrine 120 mg	300	Tab
20.	Artemether 80 mg + Lumefantrine 480 mg	1000	Tab
21.	Artesunate 50 mg	300	Tab
22.	Ascorbic acid 500 mg	40000	Tab
23.	Atorvastatin 10 mg	14000	Tab
24.	Atorvastatin 40 mg	10000	Tab
25.	Azathioprine 50 mg	1000	Tab
26.	Azithromycin 250 mg	12000	Tab
27.	Azithromycin 500 mg	25000	Tab
28.	B Complex	40200	Tab/Cap
29.	Baclofen 10 mg	1000	Tab
30.	Betamethasone 0.5 mg	1800	Tab
31.	Bicalutamide 50 mg	1000	Tab
32.	Biotin 10 mg	1300	Tab
33.	Bisacodyl 5 mg	3500	Tab
34.	Bosentan 62.5 mg	200	Tab
35.	Cabergolin 0.5 mg	3000	Tab
36.	Calcium + Vitamin D 250 mg	15,000	Tab
37.	Calcium carbonate 250 mg	13200	Tab

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

38.	Calcium polystyrene sulphonate 15 g (K exchange resin)	20	Sachet
39.	Calcitriol 0.25 mcg	100	Tab
40.	Capecitabine 500 mg	6000	Tab
41.	Carbamazepine 100 mg	2000	Tab
42.	Carbamazepine 200 mg	10200	Tab
43.	Carbamazepine CR 400 mg	4000	Tab
44.	Carbimazole 5 mg	1000	Tab
45.	Cefadroxil 500 mg	10000	Tab
46.	Cefixime 200 mg	25000	Tab
47.	Cefixime 400 mg	6000	Tab
48.	Cefuroxime 500 mg	6000	Tab
49.	Cetirizine 10 mg	5000	Tab
50.	Chloroquine 150 mg	1000	Tab
51.	Chlorpheniramine 4 mg	1000	Tab
52.	Cholecalciferol 60,000 IU	2500	Tab
53.	Chlorthalidone 6.25 mg	3700	Tab
54.	Chlorthalidone 12.5 mg	1500	Tab
55.	Cinnarizine 25 mg	1000	Tabsssss
56.	Ciprofloxacin 250 mg	600	Tab
57.	Ciprofloxacin 500 mg	26000	Tab
58.	Clarithromycin 250 mg	300	Tab
59.	Clindamycin 150 mg	2000	Cap
60.	Clindamycin 300 mg	5000	Cap
61.	Clobazam 5 mg	4200	Tab
62.	Clofazimine 50 mg	1000	Cap
63.	Clomiphene 50 mg	9000	Tab
64.	Clonazepam 0.25 mg	12000	Tab
65.	Clonazepam 1 mg	11000	Tab
66.	Clonidine 0.1 mg	2800	Tab
67.	Clopidogrel 75 mg	8000	Tab
68.	Cloxacillin 250 mg	300	Cap
69.	Clozapine 100 mg	2500	Tab
70.	Clozapine 25 mg	2500	Tab
71.	Colchicine 0.5 mg	6000	Tab
72.	Cotrimoxazole [Sulphamethoxazole 400 mg + Trimethoprim 80 mg]	3000	Tab
73.	Cotrimoxazole [Sulphamethoxazole 800 mg + Trimethoprim 160 mg]	2700	Tab
74.	Cyanocobalamin 1500 mcg	600	Tab
75.	Cyclophosphamide 50 mg	300	Tab
76.	Cyclophosphamide 200 mg	300	Tab
77.	Cyclosporine 25 mg	50	Cap
78.	Cyclosporine 50 mg	100	Cap
79.	Dapagliflozin 10 mg	7500	Tab
80.	Dapagliflozin 5 mg	5000	Tab
81.	Dapsone 50 mg	300	Tab
82.	Dexamethasone 0.5 mg	3000	Tab
83.	Dexamethasone 1 mg	600	Tab

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

84.	Dexamethasone 4 mg	3300	Tab
85.	Diclofenac Sodium 50 mg enteric coated	22500	Tab
86.	Dicyclomine 10 mg	3600	Tab
87.	Dienogest 2 mg	1200	Tab
88.	Diethylcarbamazine dihydrogen citrate 100 mg	600	Tab
89.	Digoxin 0.25 mg	3300	Tab
90.	Diltiazem 60 mg	1000	Tab
91.	Disulfiram 250 mg	2400	Tab
92.	Domperidone 10 mg	20400	Tab
93.	Doxycycline 100 mg	27000	Tab
94.	Drospirenone 3 mg + Ethinyl estradiol 0.02 mg	600	Tab
95.	Enalapril maleate 5 mg	13200	Tab
96.	Erlotinib 150 mg	1000	Tab
97.	Erythromycin 500 mg	6000	Tab
98.	Erythromycin 333 mg	700	Tab
99.	Escitalopram 10 mg	27000	Tab
100.	Estradiol 2 mg	3000	Tab
101.	Etophylline + Theophylline 300 mg CR	3000	Tab
102.	Faropenem 300 mg	6000	Tab
103.	Ferrous salt 100 mg of elemental iron + Folic acid 500 mcg	600	Tab
104.	Ferrous salt 60 mg of elemental iron +Folic acid 400 mcg	1200	Tab
105.	Ferrous sulphate 200 mg	18600	Tab
106.	Fluconazole 100 mg	300	Tab
107.	Fluconazole 150 mg	16400	Tab
108.	Fluconazole 200 mg	300	Tab
109.	Fluconazole 400 mg	600	Tab
110.	Flucytosine 500 mg	150	Tab
111.	Fludrocortisone 100 mcg	200	Tab
112.	Fluoxetine 20 mg	12000	Cap
113.	Folic acid 5 mg	31500	Tab
114.	Furosemide 40 mg	10200	Tab
115.	Gefitinib 250 mg	600	Tab
116.	Glimepiride 1 mg	6000	Tab
117.	Glimepiride 2 mg	6000	Tab
118.	Glyceryl trinitrate 0.5 mg sublingual	60	Tab
119.	Glyceryl trinitrate 10 mg	1200	Tab
120.	Glyceryl trinitrate 2.6 mg	3000	Tab
121.	Haloperidol 5 mg	2400	Tab
122.	Hydrocortisone 5 mg	400	Tab
123.	Hydroxychloroquine phosphate 200 mg	6600	Tab
124.	Hydroxyurea 500 mg	600	Cap
125.	Hyoscine butyl bromide 10 mg	6000	Tab
126.	Ibandronate 150 mg	6000	Tab
127.	Ibuprofen 200 mg	1200	Tab
128.	Ibuprofen 400 mg	27600	Tab
129.	Imatinib 400 mg	1000	Tab
130.	Isosorbide dinitrate 5 mg	300	Tab

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

131.	Isosorbide dinitrate 20 mg + Hydralazine 37.5 mg	200	Tab
132.	Isosorbide-5-mononitrate SR 30 mg	5500	Tab
133.	Isotretinoin 20 mg	12000	Tab
134.	Ispaghula granules (10 gm)	6000	Sachet
135.	Itraconazole 100 mg	18450	Tab
136.	Ivermectin 6 mg	300	Tab
137.	Labetalol 100 mg	18600	Tab
138.	Labetalol 200 mg	2500	Tab
139.	Leflunomide 10 mg	5000	Tab
140.	Leflunomide 20 mg	5000	Tab
141.	Letrozole 2.5 mg	6000	Tab
142.	Levetiracetam 500 mg	1800	Tab
143.	Levocetirizine 5 mg + Montelukast 10 mg	2100	Tab
144.	Levocetirizine 2.5 mg + Montelukast 5 mg	200	Tab
145.	Levodopa 100 mg + Carbidopa 10 mg	1800	Tab
146.	Levofloxacin 500 mg	8500	Tab
147.	Levothyroxine 100 mcg (100 tab/bottle)	3500	Tab
148.	Levothyroxine 25 mcg (100 tab/bottle)	2700	Tab
149.	Levothyroxine 50 mcg (100 tab/bottle)	8200	Tab
150.	Linagliptin 5 mg	5000	Tab
151.	Linezolid 600 mg	9000	Tab
152.	Lithium Carbonate 300 mg	6000	Tab
153.	Loperamide 2 mg	2400	Tab
154.	Lorazepam 1 mg	13200	Tab
155.	Medroxyprogesterone acetate 10 mg	12000	Tab
156.	Mefenamic acid 250 mg	2700	Cap
157.	Melphalan 5 mg	200	Tab
158.	Metformin SR 500 mg	13000	Tab
159.	Methotrexate 2.5 mg	10,000	Tab
160.	Methotrexate 15 mg	700	Tab
161.	Methotrexate 5 mg	10,000	Tab
162.	Methylcobalamine 500 mcg	1200	Tab
163.	Methyldopa 250 mg	600	Tab
164.	Methylprednisolone 8 mg	200	Tab
165.	Metoclopramide 10 mg	10200	Tab
166.	Metoprolol SR 25 mg	4800	Tab
167.	Metronidazole 200 mg	19500	Tab
168.	Metronidazole 400 mg	10000	Tab
169.	Mifepristone 25 mg	200	Tab
170.	Mifepristone 200 mg	1200	Tab
171.	Misoprostol 200 mcg	3600	Tab
172.	Misoprostol 25 mcg	1000	Tab
173.	Moxifloxacin 200 mg	600	Tab
174.	Mycophenolatemofetil 250 mg	400	Tab
175.	Mycophenolatemofetil 500 mg	400	Tab
176.	N- Acetyl cysteine 600 mg	600	Tab
177.	Naproxen 250 mg	3000	Tab
178.	Naproxen 500 mg	3000	Tab
179.	Nifedipine 10 mg SR	6000	Tab



**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

180.	Nitazoxanide 500 mg	600	Tab
181.	Nitrofurantoin 100 mg	130000	Tab
182.	Norethisterone 5 mg	6000	Tab
183.	Norethisterone SR 10 mg	1000	Tab
184.	Norethisterone SR 15 mg	1000	Tab
185.	Olanzapine 5 mg	6000	Tab
186.	Omeprazole 10 mg	600	Cap
187.	Omeprazole 20 mg	24000	Cap
188.	Ondansetron 4 mg	38000	Tab
189.	Ondansetron 8 mg	6000	Tab
190.	Oral rehydration salts	33000	Sachet
191.	Pantoprazole 40 mg	44000	Tab
192.	Paracetamol 500 mg	70000	Tab
193.	Paracetamol 650 mg	54000	Tab
194.	Penicillamine 250 mg	200	Cap
195.	Phenobarbitone 60 mg	300	Tab
196.	Phenytoin sodium 100 mg (120 tablets/bottle)	3000	Tab
197.	Prazosin 5 mg XL	1200	Tab
198.	Prednisolone 10 mg	1500	Tab
199.	Pregabalin 75 mg	1200	Tab
200.	Primaquine 7.5 mg	2000	Tab
201.	Procarbazine 50 mg	300	Cap
202.	Propranolol HCl 10 mg	2400	Tab
203.	Propranolol HCl 40 mg SR	4300	Tab
204.	Propylthiouracil 50 mg	600	Tab
205.	Pyridoxine 50 mg	2000	Tab
206.	Ramipril 5 mg	3000	Tab
207.	Ranitidine 150 mg	23000	Tab
208.	Riboflavin 5 mg	3500	Tab
209.	Rifampicin 150 mg	30	Cap
210.	Rifampicin 450 mg	300	Cap
211.	Rifaximin 550 mg	300	Tab
212.	Risperidone 2 mg	12000	Tab
213.	Salbutamol 2 mg	2400	Tab
214.	Sildenafil 25mg	200	Tab
215.	Sitagliptin 100 mg	3000	Tab
216.	Sodium bicarbonate 500 mg	300	Tab
217.	Sodium valproate CR 200 mg	9600	Tab
218.	Sodium valproate CR 300 mg	1200	Tab
219.	Sodium valproate CR 500 mg	7200	Tab
220.	Sotalol 80 mg	20	Tab
221.	Spirolactone 25 mg	8200	Tab
222.	Sulfasalazine 500 mg	3000	Tab
223.	Tacrolimus 0.5 mg	6000	Cap
224.	Tacrolimus 1 mg	5000	Cap
225.	Tamoxifen 10 mg	4500	Tab
226.	Tamoxifen 20 mg	1500	Tab
227.	Telmisartan 40 mg	12600	Tab
228.	Temozolamide 100 mg	50	Cap

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

229.	Temozolamide 250 mg	50	Cap
230.	Thalidomide 100 mg	300	Cap
231.	Thiamine 100 mg	3400	Tab
232.	Tofacitinib 5 mg	4000	Tab
233.	Tramadol 100 mg	3000	Cap
234.	Tramadol 50 mg	48000	Cap
235.	Tranexamic acid 500 mg	12000	Tab
236.	Trihexyphenidyl 2 mg	6000	Tab
237.	Valganciclovir 450 mg	1200	Tab
238.	Vitamin A 50,000 IU	1800	Tab
239.	Vitamin B complex NFI vitamin B1 IP 2 mg + vitamin B2 IP 2 mg + vitamin B6 IP 0.5 mg + niacinamide IP 25 mg + calcium pantothenate IP 1 mg	7500	Tab/Cap
240.	Vitamin D 60,000 IU	17000	Cap
241.	Warfarin 2 mg	6000	Tab
242.	Warfarin sodium 5 mg	1500	Tab
243.	Zinc sulphate 50 mg	1200	Tab
244.	Zolpidem 5 mg	1500	Tab
<b>INJECTABLE DRUGS</b>			
Ampoules should be machine sealed. Vials should be fresh and embossed with same mark for a batch. Each pack of ampoules should contain at least 5 metallic files/ampoule cutters. Samples of all intravenous fluids must reach the Store Section before the last date. Each Pack should not contain more than TEN Ampoules/Vials.			
245.	Acetaminophen 1000 mg/100ml	2200	Vial
246.	Acetyl cysteine 200 mg	200	Amp/Vial
247.	ACTH 60 IU	60	Amp/Vial
248.	Actinomycin D 0.5 mg	10	Vial
249.	Acyclovir 50 mg	300	Vial
250.	Acyclovir 500 mg	1000	Vial
251.	Adalimumab 40 mg	100	PFS
252.	Adenosine 6mg/2ml	300	Amp
253.	Adrenaline tartrate (1:1000) 1 ml	1500	Amp/Vial
254.	Alteplase 20 mg	50	Vial
255.	Alteplase 50 mg	50	Vial
256.	Amikacin 250 mg	400	Vial
257.	Amikacin 500 mg	7200	Vial
258.	Amikacin 1 g	800	Vial
259.	Aminophylline 250 mg	120	Amp/Vial
260.	Amiodarone 150 mg/3ml	300	Amp
261.	Amoxicillin 1 g + Clavulanic acid 200 mg	30000	Vial
262.	Amphotericin B conventional 50 mg	1700	Vial
263.	Amphotericin B liposomal 50 mg	1200	Vial
264.	Ampicillin 1 g	600	Vial
265.	Ampicillin 500 mg	7800	Vial
266.	Anti D Rh factor human immunoglobulin monoclonal 300 mcg	1200	Vial/ PFS
267.	Anti D Rh factor human immunoglobulin 150 mcg	300	Vial

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

268.	Anti-diphtheritic serum	60	Vial
269.	Anti-rabies immunoglobulin	60	Vial
270.	Anti-rabies vaccine	60	Vial
271.	Anti-tetanus immunoglobulin 250 IU/ml	30	Vial
272.	Artesunate 60 mg	500	Vial
273.	Atracurium 10 mg/ml	1500	Amp
274.	Atropine sulphate 0.6 mg/ml	7000	Amp
275.	Atropine sulphate 1 mg/ml 100 ml	700	Vial
276.	Azithromycin 500 mg	24000	Vial
277.	Aztreonam 500 mg	300	Amp/Vial
278.	Benzathine penicillin 1.2 million U	60	Vial
279.	Benzathine penicillin 2.4 million U	60	Vial
280.	Beractant 25 mg/ml intratracheal solution 8 ml	60	Vial
281.	Bevacizumab 300 mg	10	Amp/Vial
282.	Bevacizumab 100 mg	50	Amp/Vial
283.	Bevacizumab 400 mg	20	Amp/Vial
284.	Bleomycin 15 IU	60	Vial
285.	Bortezomib 2 mg	100	Vial
286.	Bupivacaine 0.5% + Dextrose 8% 4 ml	1500	Ampoule
287.	Bupivacaine 0.5% 20 ml	500	Vial
288.	Buprenorphine 0.3 mg/ml	150	Amp
289.	Caffeine citrate 20 mg/ml	500	Amp/Vial
290.	Calcium gluconate 10%	3300	Amp/Vial
291.	Carbetocin 1 ml	3000	Amp/Vial
292.	Carboplatin 150 mg	100	Amp/Vial
293.	Carboplatin 450 mg	100	Amp/Vial
294.	Carbopost 250 mcg	500	Amp/Vial
295.	Caspofungin 70 mg/ml	60	Vial
296.	Cefazolin 1 g	7800	Vial
297.	Cefazolin 500 mg	800	Vial
298.	Cefepime 1 g	800	Vial
299.	Cefoperazone 1 g + Sulbactam 500 mg	4800	Vial
300.	Cefotaxime 125 mg	600	Vial
301.	Cefotaxime sodium 1 g	6000	Vial
302.	Ceftazidime 1 g + Sulbactam 500 mg	300	Vial
303.	Ceftazidime 1 g	3200	Vial
304.	Ceftazidime 250 mg	700	Vial
305.	Ceftriaxone 1 g	31000	Vial
306.	Ceftriaxone 250 mg	6100	Vial
307.	Cefuroxime 1.5 g	800	Vial
308.	Chlorpheniramine maleate 10 mg/ml 1 ml	6600	Amp
309.	Cholecalciferol 6 lac IU	600	Amp
310.	Ciprofloxacin 200 mg/100 ml	19000	Bottle
311.	Cisatracurium 2 mg/ml 5ml	300	Amp/Vial
312.	Cisplatin 10 mg	10	Vial
313.	Cisplatin 50 mg	120	Vial
314.	Clindamycin phosphate 300 mg/2 ml	4200	Amp
315.	Clonidine 150 mcg/ml 1 ml	100	Amp

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

316.	Cloxacillin 1 g	900	Vial
317.	Colistimethate sodium powder 1 MIU/10 ml	200	Vial
318.	Colistimethate sodium powder 4.5 MIU/10 ml	100	Vial
319.	Cotrimoxazole (160 mg + 800 mg)	200	Vial
320.	Cyclophosphamide 200 mg	100	Vial
321.	Cyclophosphamide 500 mg	30	Vial
322.	Cyclophosphamide 1 g	150	Vial
323.	Dacarbazine 200 mg	30	Vial
324.	Dacarbazine 500 mg	20	Vial
325.	Darbepoietin alfa 40mcg	50	PFS
326.	Deferoxamine 500 mg	60	Vial
327.	Desmopressin 4 mcg/ml 1ml	20	Vial
328.	Dexamethasone 4 mg/ml	11700	Amp
329.	Dexamethasone 8 mg/2 ml	3600	Vial
330.	Dexmedetomidine 100 mcg/ml	150	Amp
331.	Diazepam 10 mg/ml	500	Amp
332.	Diclofenac sodium aq 75 mg/3 ml	30500	Amp
333.	Dicyclomine 10 mg/ml	650	Amp
334.	Digoxin 0.25 mg/ml	780	Amp/Vial
335.	Diltiazem 5 mg/ml 5 ml	360	Vial
336.	DMPA 150 mg	3000	Amp/Vial
337.	Dobutamine 250 mg/5 ml	6400	Amp/Vial
338.	Docetaxel 20 mg	150	Vial
339.	Docetaxel 80 mg	200	Vial
340.	Docetaxel 120 mg	150	Vial
341.	Dopamine 200 mg/5 ml	7500	Amp/Vial
342.	Doxorubicin 10 mg	200	Amp/Vial
343.	Doxorubicin 50 mg	200	Amp/Vial
344.	Doxorubicin liposomal 20 mg	20	Amp
345.	Doxycycline 100 mg	900	Vial
346.	Drotaverine 40 mg	30	Vial
347.	Drotaverine 80 mg	30	Vial
348.	<b>Enalaprilat 2.5 mg/2ml</b>	<b>50</b>	<b>Amp</b>
349.	Enoxaparin 10 mg/0.1 ml 40 mg	1500	PFS
350.	Enoxaparin 10 mg/0.1 ml 60 mg	5000	PFS
351.	Epirubicin 10 mg	60	Vial
352.	Epirubicin 50 mg	60	Vial
353.	Epirubicin 100 mg	60	Vial
354.	Erythropoietin 2000 IU	150	Vial
355.	Esmolol 10 mg/ml	250	Vial
356.	Etomidate 20 mg/10 ml	50	Vial
357.	Etophylline + Theophylline 220 mg/2 ml	6300	Amp
358.	Etoposide 100 mg	200	Amp/Vial
359.	Factor IX Recombinant, Fc Fusion Protein-1 600 U	20	Vial
360.	Factor VII a, recombinant 1 mg	20	Vial

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

361.	Factor VIII-Plasma Recombinant 250 IU	20	Vial Vial
362.	Factor Xa Recombinant 100 mg	20	Vial
363.	Factor XIII concentrate human 1000-1600 IU	20	Vial
364.	Ferric carboxymaltose 500 mg/10 ml	150	Vial
365.	Filgrastim 300 mcg	200	PFS
366.	Fluconazole 200 mg/100 ml	800	Bottle
367.	Flumazenil 0.1 mg/ml	60	Amp/Vial
368.	Fluorescein sodium 20% 3 ml	200	Amp/Vial
369.	5-Fluorouracil 250 mg	100	Amp/Vial
370.	5-Fluorouracil 500 mg	100	Amp/Vial
371.	Folic acid 5 mg/ml	60	Amp/Vial
372.	Folinic Acid 50 mg	100	Vial
373.	Fomepizole 1.5 g/1.5 ml	20	Amp/Vial
374.	Fondaparinux 2.5 mg	10	Amp/Vial
375.	Fondaparinux 7.5 mg	10	Amp/Vial
376.	Fosaprepitant 150 mg	120	Amp/Vial
377.	Fosfomycin 4 g	20	Amp/Vial
378.	Fosphenytoin 50 mg/ml	300	Amp/Vial
379.	Furosemide 10 mg/ml	13700	Amp
380.	Ganciclovir 500 mg	300	Vial
381.	Gemcitabine 200 mg	300	Vial
382.	Gemcitabine 1 g	300	Vial
383.	Gentamicin 40 mg/ml	12200	Amp
384.	Glucagon 1 mg	50	Vial
385.	Glyceryl trinitrate 5 mg/ml	1200	Amp/Vial
386.	Glycopyrrolate 0.2 mg/ml	4400	Amp
387.	Haloperidol 5 mg/ml	300	Amp
388.	Heparin 1000 IU/ml	5100	Vial
389.	Heparin 5000 IU/ml	600	Vial
390.	Hepatitis B immunoglobulin 100IU/0.5ml	600	Vial
391.	Human normal serum albumin 20% 100 ml	250	Vial
392.	Human immune globulin 5% 100 ml	30	Vial
393.	Hyaluronidase 1500 IU	50	Vial/Amp
394.	Hydralazine 20 mg	1300	Amp/Vial
395.	Hydrocortisone 100 mg	5400	Vial
396.	Hyoscine butyl bromide 10 mg	30	Amp/Vial
397.	Hyoscine butyl bromide 20 mg	1500	Amp/Vial
398.	Hypertonic saline 3%	18000	Vial
399.	Ifosfamide 2 g + MESNA 1200 mg	120	Vial
400.	Imipenem + Cilastatin 500 mg	50	Vial
401.	Indomethacin 1 mg	100	Vial
402.	Infliximab 100 mg	50	Vial
403.	Insulin soluble 40 IU/ml	6700	Vial
404.	Insulin glargine 100 IU/ml	50	Vial
405.	Insulin isophane/NPH 70% + Human insulin soluble 30%	2400	Vial

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

406.	Insulin NPH 40 IU/ml	1200	Vial
407.	Irinotecan 100 mg	30	Vial
408.	Iron isomaltoside 1 g	100	Bottle
409.	Ferric carboxymaltose 500 mg	100	Bottle
410.	Isoflurane 250 ml	600	Bottle
411.	Isoprenaline 2 mg/ml 1 ml	80	Ampoule
412.	Ketamine 50 mg/ml 10 ml	600	Vial
413.	Labetalol 5 mg/ml	600	Amp/Vial
414.	Leucovorin 50 mg	200	Vial
415.	Leuprolide 11.25 mg	200	Amp/Vial
416.	Levetiracetam 100 mg/ml 5 ml	300	Vial
417.	Levosimendan 12.5 mg	60	Amp/Vial
418.	Lignocaine 2% 20 ml (preservative free)	80	Vial
419.	Lignocaine 2% 20 ml	1500	Vial
420.	Lignocaine 4% 20 ml	20	Vial
421.	Lignocaine HCl 2% with Adrenaline (0.005 mg to 0.0125 mg) 30 ml	400	Vial
422.	Linezolid 600mg	150	Bottle
423.	Lorazepam 2 mg	6300	Amp
424.	Magnesium sulphate 500 mg/ml	4700	Amp/Vial
425.	Magnesium sulphate 200 mg/ml	3000	Amp/Vial
426.	Mannitol 20% 100 ml	1000	Bottle
427.	Mephentermine 30 mg/ml 10 ml	150	Vial
428.	Meropenem 125 mg	6700	Vial
429.	Meropenem 500 mg	6200	Vial
430.	Meropenem 1 g	1500	Vial
431.	Methotrexate 15 mg	3000	Vial
432.	Methotrexate 50 mg	60	Vial
433.	Methyl ergometrine 0.2 mg	750	Amp/Vial
434.	Methyl prednisolone 40 mg	500	Vial
435.	Methyl prednisolone 500 mg	30	Amp/Vial
436.	Methylcobalamine 1000 mcg	200	Amp/Vial
437.	Methylene blue 10 mg/ml	900	Vial
438.	Metoclopramide 5 mg/ml	600	Amp
439.	Metoprolol 5 mg/5 ml	50	Amp
440.	Metronidazole 500 mg/100 ml	500	Bottle
441.	Midazolam 1 mg/ml 10 ml	1200	Vial
442.	Milrinone 1 mg/ml	400	Amp
443.	Mitomycin C 10 mg	5	Amp
444.	Multivitamin injection mvi	200	Amp
445.	N- acetyl cysteine 200 mg/ml 5 ml	14000	Amp/Vial
446.	Nab- Paclitaxel 100 mg	30	Amp/Vial
447.	Naloxone HCl 400 mcg/ml	300	Amp
448.	Neostigmine 0.5 mg/ml 5 ml	1200	Amp
449.	Nicardipine 25 mg/10 ml	180	Vial

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

450.	Nitroglycerine 25 mg/5 ml	30	Amp
451.	Noradrenaline bitartrate 4 mg/2 ml	7800	Amp
452.	Octreotide 100 mcg/ml	150	Amp
453.	Ondansetron 4 mg	1500	Amp
454.	Ondansetron 8 mg	120	Amp
455.	Oxaliplatin 50 mg	300	Vial
456.	Oxaliplatin 100 mg	80	Vial
457.	Oxytocin 10 IU/ml	1500	Amp
458.	Paclitaxel 100 mg	7200	Amp/Vial
459.	Paclitaxel 260 mg	300	Amp/Vial
460.	Palivizumab 50 mg/0.5 ml	20	Amp
461.	Palonosetron 0.25 mg	600	Amp/Vial
462.	Pantoprazole 40 mg	1500	Vial
463.	Paracetamol 150 mg/ml	15000	Amp
464.	Pemetrexed 100 mg	30	Amp
465.	Pemetrexed 500 mg	30	Amp
466.	Penicillin G 5 Lac IU	1000	Vial
467.	Pentazocine 30 mg/ml	100	Vial
468.	Pethidine 50 mg/ml	100	Amp
469.	Pheniramine maleate 4 mg	6000	Amp
470.	Pheniramine 45.5 mg/2 ml	300	Amp
471.	Phenobarbitone 200 mg/ml	800	Amp/Vial
472.	Phenobarbitone 100 mg/ml	200	Amp/Vial
473.	Phentolamine 10 mg/ml	20	Amp
474.	Phenylephrine 10 mg/ml 1 ml	50	Amp
475.	Phenytoin 50 mg/ml	1500	Amp
476.	Phytomenadione 10 mg/ml	2600	Amp
477.	Phytomenadione 1 mg/0.5 ml	1200	Amp
478.	Piperacillin 1 g +Tazobactam 125 mg	1000	Amp
479.	Piperacillin 4 g + Tazobactam 500 mg	14000	Vial
480.	Procaine penicillin 6 lac U	1000	Vial
481.	Potassium chloride 2 mEq/ml	5000	Amp/Vial
482.	Pralidoxime chloride (2 ppm) 25 mg/ml	300	Amp/Vial
483.	Prednisolone 20 mg/2 ml	50	Amp
484.	Procainamide 1g/10ml	200	Vial
485.	Promethazine 25 mg/ml	2700	Vial
486.	Propofol 10 mg/ml 10 ml	1400	Vial
487.	Propofol infusion 50 ml	300	Vial
488.	Prostaglandin E1 0.5mg/ml	200	Amp
489.	Protamine sulphate 10 mg/ml	500	Amp/Vial
490.	Pyridoxine 100 mg/ml	350	Amp/Vial
491.	Quinine 300 mg/100 ml	50	Vial
492.	Quinupristin/Dalfopristin 500 mg	20	Vial
493.	Ranibizumab 10 mg/ml	10	Amp/Vial
494.	Ranitidine 25 mg/ml	4000	Amp
495.	Rituximab 100 mg	30	Vial

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

496.	Rituximab 500 mg	20	Vial
497.	Rocuronium 50 mg/5 ml	600	Amp/Vial
498.	Ropivacaine 0.75% 20 ml	600	Amp
499.	Sargramostim 500 mcg	60	Vial
500.	Sevoflurane 250 ml bottle	600	Bottle
501.	Snake venom antiserum lyophilized polyvalent	2000	Vial
502.	Sodium bicarbonate 7.5% 10 ml	1500	Vial
503.	Sodium nitroprusside 25 mg/ml	50	Amp
504.	Sodium phenyl acetate 10% 50 ml	20	Vial
505.	Sodium valproate 100 mg/ml	700	Amp/Vial
506.	Streptokinase 15,00,000 IU/ml	150	Vial
507.	Succinyl choline 50 mg/ml	150	Amp
508.	Surfactant 80 mg/ml intratracheal solution	150	Amp/Vial
509.	Teicoplanin 400 mg	1500	Amp/Vial
510.	Tenecteplase 30 mg	10	Amp/Vial
511.	Tenecteplase 20 mg	10	Amp/Vial
512.	Tenecteplase 40 mg	10	Amp/Vial
513.	Tetanus toxoid 0.5 ml	8100	Amp
514.	Thiamine 100 mg/ml	1300	Amp/Vial
515.	Thiopentone 0.5 g	300	Vial
516.	Ticarcillin clavulanate 3.1 g	200	Vial
517.	Tigecycline 50 mg	600	Amp/Vial
518.	Trace elements 10 ml	200	Vial
519.	Tramadol 50 mg	21500	Amp/Vial
520.	Tranexamic acid 500 mg/5 ml	13000	Amp/Vial
521.	Trastuzumab Emtansine 100 mg	8	Vial
522.	Trastuzumab Emtansine 160 mg	8	Vial
523.	Trastuzumab 150 mg	10	Vial
524.	Trastuzumab 440 mg/50 ml	10	Vial
525.	Triamcinolone acetonide 40 mg/ml	6600	Vial
526.	Tuberculin purified protein derivative 5 IU/0.1 ml	100	Vial
527.	Vaccine hepatitis B recombinant human	800	Vial
528.	Vancomycin 500 mg	5500	Vial
529.	Varicella zoster immunoglobulin 125 IU	40	Vial
530.	Vasopressin 20 IU/ml	30	Amp
531.	Vecuronium 1 mg/ml	150	Vial
532.	Vincristine 1 mg	60	Vial
533.	Voriconazole 200 mg	400	Vial
534.	Water for Injection	27600	Bottle
535.	Zidovudine 10 mg/ml	60	Amp/Vial
536.	Zoledronic acid 4 mg	6200	Vial
537.	{Low osmolar iodinated contrast agent (Non-ionic monomer)} Iohexol/iopromide/lopamidol (350mg/ml) 100ml	400	Vial



**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

538.	{Low osmolar iodinated contrast agent (Non-ionic monomer)} Iohexol/iopromide/lopamidol (350mg/ml) 50ml	100	Vial
539.	Iso-osmolar iodinated contrast agent ( Non-ionic dimer) Lodixanol (320mg/ml) 100ml	50	Vial
540.	GD based MR contrast agent (Gadobutrol /Gadoterate Meglumine) (1 mmol/ml) 5ml	50	Vial
541.	GD based MR contrast agent (Gadobutrol/ Gadoterate Meglumine) (0.5mmol/ml) 10ml vial	50	Vial
542.	GD based hepatocyte specific MR contrast agent Gadobenate Dimeglumine (Gd- BOPTA) Gadoxetate disodium (Gd- EOB DTPA) (0.5mmol/ml) 10ml vial	20	Vials
543.	Ultrasound Contrast agent (Sulphur hexafluoride microbubbles)	3	Vial
544.	Ultrasound Contrast agent (Perfluorobutone microbubbles)	3	Vial
<b>PREPARATIONS FOR EXTERNAL USE</b>			
545.	Acyclovir eye ointment 3% 5 g	400	Tubes
546.	Bacitracin 400 IU + Neomycin 3400 IU + Polymyxin B 5000 IU ointment 5 g	300	Tubes
547.	Calamine lotion 100 ml	7500	Bottle
548.	Chlorhexidine gluconate + Metronidazole gel	600	Tubes
549.	Ciprofloxacin 0.3% eye ointment 5 g	1800	Tubes
550.	Clotrimazole cream 1% 10 gm	700	Tubes
551.	Clotrimazole Pessary 100 mg	600	Pessary
552.	Coal tar solution 5%	600	Bottle
553.	Fluconazole 0.5% gel 15gm	200	Tubes
554.	Fluocinolone acetonide cream 30gm	300	Tubes
555.	Framycetin 1% ointment	50	Tubes
556.	Fusidic acid 2% 10 g	1500	Tubes
557.	Heparin 50 IU + Benzyl Nicotinate 2 mg ointment 20 g	150	Tubes
558.	Hydrocortisone 1% cream 15gm	3000	Tubes
559.	Lignocaine HCl 2% w/v 30 g	300	Tubes
560.	Lignocaine 2.5% + Prilocaine 2.5%	200	Tubes
561.	Mupirocin 2% ointment 5 g	1600	Tubes
562.	Paracetamol suppositories 250 mg	60	Suppository
563.	Permethrin 5% 15 g	100	Tubes
564.	Povidone iodine ointment 5% 15 g	3300	Tubes
565.	Silver sulphadiazine 1% 25 g	200	Tubes
<b>EYE AND ENT PREPARATIONS</b>			
566.	Beclomethasone 0.025% w/v + Chloramphenicol 5% w/v + Clotrimazole 1.0% w/v + Lignocaine 2% w/v 5 ml	200	Bottle
567.	Brimonidine eye drops 0.15% 5 ml	200	Bottle
568.	Budesonide 0.5 mg/ml 2 ml	15	Bottle
569.	Carboxymethyl cellulose 0.5 % eye drops 5 ml	500	Bottle
570.	Carboxymethyl cellulose 1% eye drops 5 ml	200	Bottle

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

571.	Chloramphenicol + Polymyxin-B sulphate ointment	100	Tubes
572.	Clotrimazole 1.0% w/v	150	Bottle
573.	Cyclopentolate eye drops 1% 5 ml	100	Bottle
574.	Dorzolamide 2% eye drops 5 ml	100	Bottle
575.	Flurbiprofen eye drops 0.03% 5 ml	50	Bottle
576.	Fluticasone 27.5 mcg nasal spray	100	Bottle
577.	Gentamicin Drops 0.3% 5 ml	600	Bottle
578.	Homatropine 2% eye drops 5 ml	100	Bottle
579.	Hydroxymethyl cellulose 2%	100	Pre-filled syringes
580.	Latanoprost 50 mcg eye drops 2.5 ml	10	Bottle
581.	Moxifloxacin 0.5% eye drops 5 ml	500	Bottle
582.	Natamycin Drops 5% 3 ml	40	Bottle
583.	Phenylephrine 10% 15ml	60	Bottle
584.	Pilocarpine Drops 2% 5 ml	100	Bottle
585.	Povidone iodine solution 10% 5ml (non-irritant to eyes)	1000	Bottle
586.	Prednisolone acetate 1 % eye drops 5 ml	500	Bottle
587.	Proparacaine HCl 0.5% eye drops 5 ml	100	Bottle
588.	Sodium chloride 0.65% w/v to 0.8% w/v with preservatives nasal drops 5 ml	1000	Bottle
589.	Timolol 0.5% eye drops 5 ml	200	Bottle
590.	Tropicamide 1% 5 ml	100	Bottle
591.	Trypan blue dye 0.4%	200	Bottle
592.	Sodium chloride 6% ointment 3 g	10	Tubes
593.	Sodium hyaluronate 1.4% 1 ml	10	Pre-filled syringes
594.	Xylometazoline nasal drops 0.05% w/v 15 ml	1000	Bottle
595.	Xylometazoline nasal drops 0.1% w/v 10 ml	1000	Bottle
<b>ORAL SYRUPS, SOLUTIONS &amp; SUSPENSIONS</b>			
596.	Acyclovir 200 mg/5 ml 100 ml	1000	Bottle
597.	Albendazole 200 mg/5 ml 10 ml	9300	Bottle
598.	Aluminium hydroxide 0.291 mg/5 ml + Magnesium hydroxide 98 mg/5 ml + Oxetacaine 10 mg/5 ml gel 200 ml	600	Bottle
599.	Ambroxol 30 mg/5 ml 100 ml	300	Bottle
600.	Amoxicillin 125 mg/5 ml 60 ml	300	Bottle
601.	Amoxicillin 250 mg/5 ml 100 ml	300	Bottle
602.	Amoxycillin and potassium clavulanate oral suspension 228 mg/5 ml 30 ml	600	Bottle
603.	Amoxycillin Clavulanate (Amoxycillin 125mg/5ml + Clavulanate 31.25 mg/5 ml) 30 ml	1000	Bottle
604.	Artemether 20 mg/5 ml + Lumefantrine 120 mg/5 ml dry syrup 60 ml	60	Bottle
605.	Artemether 80 mg+ Lumefantrine 480 mg/5 ml 30 ml	10	Bottle
606.	Azithromycin 200 mg/5ml 15 ml	3000	Bottle
607.	Azithromycin dry syrup 100 mg/5ml 30 ml	1800	Bottle

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

608.	Calcium carbonate 250 mg/5 ml + Vit D3 200 IU 5 ml	3600	Bottle
609.	Carbamazepine 100 mg/5 ml 100 ml	100	Bottle
610.	Cough syrup with Dextromethorphan 15 mg/5 ml 100 ml	1500	Bottle
611.	Cefixime 100 mg/5 ml 30 ml	2000	Bottle
612.	Cetirizine 5 mg/5 ml 30 ml	5400	Bottle
613.	Chloroquine 50 mg/5 ml 60 ml	10	Bottle
614.	Chlorpheniramine maleate 2 mg/ml 15 ml	300	Bottle
615.	Cotrimoxazole 240 mg/5 ml 100 ml	1300	Bottle
616.	Dicyclomine 10mg/5ml 60 ml	3000	Bottle
617.	Digoxin 50 mcg/ml 60 ml	100	Bottle
618.	Domperidone 1 mg/ml 30 ml	1300	Bottle
619.	Ferrous sulphate + Folic acid 20+0.1 mg/ml 200 ml	1800	Bottle
620.	Ferrous sulphate + folic acid 80 mg/5 ml 200 ml	2700	Bottle
621.	Fluconazole 10 mg/ml 60 ml	400	Bottle
622.	Fludrocortisone 0.1 mg/ml	30	Bottle
623.	Furosemide 10 mg/ml 30 ml	50	Bottle
624.	Glycerin 10% w/v 500 ml	60	Bottle
625.	Ibuprofen 100 mg/5 ml suspension 100 ml	250	Bottle
626.	Lactulose 10 g/15 ml 200 ml	1300	Bottle
627.	Levetiracetam 100 mg/ml 100 ml	200	Bottle
628.	Levosalmamol 1 mg/5 ml 100 ml	1200	Bottle
629.	Linezolid 100 mg/5 ml 30 ml	250	Bottle
630.	Metronidazole 200 mg/5 ml 60 ml	1700	Bottle
631.	Midazolam 1 mg/ml	200	Bottle
632.	Nitazoxanide 100 mg/5ml	100	Bottle
633.	Nitrofurantoin 25 mg/5 ml	300	Bottle
634.	Nystatin 100,000 IU/ml	150	Bottle
635.	Omeprazole 2 mg/ml	100	Bottle
636.	Ondansetron 2 mg/5 ml	3700	Bottle
637.	Paracetamol 125 mg/5 ml	16300	Bottle
638.	Phenobarbitone 20 mg/5 ml 60 ml	2200	Bottle
639.	Phenytoin 30 mg/5 ml	100	Bottle
640.	Potassium chloride 500 mg/5 ml	400	Bottle
641.	Prednisolone 15 mg/5 ml	800	Bottle
642.	Prednisolone 5 mg/5 ml	800	Bottle
643.	Propranolol 20 mg/5 ml 500 ml	20	Bottle
644.	Quinine 150 mg/5 ml 60 ml	20	Bottle
645.	Ranitidine 75 mg/5 ml	400	Bottle
646.	Sodium valproate 200 mg/5 ml	600	Bottle
647.	Sucrose 24% 1 ml	400	Bottle
648.	Sucralfate 1 g	30	Bottle
649.	Vitamin A 1 lac units/ml	1900	Bottle
650.	Vitamin B complex NFI 100 ml	1200	Bottle
651.	Vitamin D 400 IU/ml	4500	Bottle

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

652.	Zidovudine 50 mg/5 ml 240 ml	30	Bottle
653.	Zinc gluconate 20 mg/5 ml	4500	Bottle
<b>MISCELLANEOUS</b>			
654.	Barium sulphate high density powder (low viscosity) 300 g	30	Pack
655.	Budesonide 0.25 mg/ml 2 ml	10500	Respules
656.	Budesonide 100 mcg + Formeterol 6 mcg /dose	800	MDI Device
657.	Budesonide 200 mcg + Formeterol 6 mcg /dose	600	MDI Device
658.	Budesonide respirator solution for use innebulizer 0.5 mg/ml	600	Respules
659.	Glacial acetic acid IP 400 ml	1500	Bottle
660.	GTN Nasal spray 200 metered doses	50	Bottle
661.	Hemodialysis solution (part A) 10 liter cans	1500	Bottle
662.	Hemodialysis solution (part B)	1500	Packet
663.	Ipratropium 250 mcg/ml	10000	Respules
664.	Lignocaine 10% spray	10	Bottle
665.	Levosambutamol 1.25 mg/2.5 ml	3000	Respules
666.	Lugol's iodine IP 200 ml	50	Bottle
667.	Peritoneal dialysis fluid 2.5% 5 Litres	650	Pack
668.	Proctoglycerine enema	150	Bottle
669.	Salbutamol 2.5 mg/2.5 ml	10800	Respules
670.	Salbutamol respirator solution for use innebulizer 5 mg/ml	60	Respules
671.	Salbutamol 100 mcg per dose 200 doses MDI	7700	MDI Device
<b>IV FLUIDS</b>			
Samples for quoted IV fluids should be sent to the Store Section, Block D, AIIMS, Bilaspur (HP), before the last date of tender. All Intravenous fluids must be manufactured using FFS technology.			
672.	Amino acid solution 10% 500 ml	300	Bottle
673.	Dextrose 10% 500 ml	8000	Bottle
674.	Dextrose 25% 100 ml	800	Bottle
675.	Dextrose 5% 500 ml	8000	Bottle
676.	Dextrose 50% 50 ml	800	Bottle
677.	DNS 500 ml	15000	Bottle
678.	Hexastarch 6% 500 ml	1500	Bottle
679.	Intralipid 20% 250 ml	15	Bottle
680.	Multielectrolyte in 5% Dextrose 500 ml	200	Bottle
681.	Nutrition powder (per 100 g protein 42 g, energy 359 kCal, fat 3 g, carbohydrates 41 g, sugar 0)	2	Enteral (NG/ RT)
682.	Nutrition powder (High calorie high protein) (per 100 g protein 21 g, energy 500 kCal, fat 25.6 g, carbohydrate 48.77 g)	2	Enteral (NG/ RT)
683.	Nutrition powder (High Calorie low protein) (per 100 g protein 12 g, energy 500 kCal, fat 25.6 g, carbohydrate 52 g)	2	Enteral (NG/ RT)

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

684.	Nutrition powder (for Diabetic patients) (per 100 g protein 20 g, energy 450 kCal, fat 20 g, carbohydrates 43.8 g, sugar 0)	2	Enteral (NG/ RT)
685.	Ringer lactate 500 ml	15000	Bottle
686.	Sodium chloride 0.45% 500 ml	3000	Bottle
687.	Sodium chloride 0.9% 100 ml	3000	Bottle
688.	Sodium chloride 0.9% 500 ml	30000	Bottle
689.	Sodium chloride 3% 100 ml	2000	Bottle
690.	Total Parenteral Nutrition solution in 3 chamber single bag having PVC free, DEHP free container with needle free access and latex free injection port with strong hanger. Volume should be 1400- 1500 ml. Calories provided should be 800-1000 kilocalories, Glucose 90- 110 g per 1500 ml, protein content should be 30-50 g per 1500 ml, lipid emulsion should be 30-50 g per 1500 ml with a mixture of LCT, MCT, olive oil/ fish oil /Soya oil. Should also contain micro nutrients like trace elements, zinc and taurine. Should have an osmolality permitting to be infused through peripheral vein (< 900 mosm/L)	2	Bag
691.	Total Parenteral Nutrition solution in 3 chamber single bag having PVC free, DEHP free container with needle free access and latex free injection port with strong hanger. Volume should be 1400 – 1500 ml. Calories provided should be 1500-1600 kilocalories, Glucose 170- 190 g per 1500 ml, protein content should be 60- 75 g per 1500 ml, lipid emulsion should be 50- 60 g per 1500 ml, with a mixture of LCT, MCT, olive oil/ fish oil /Soya oil. Should also contain micronutrients like trace elements, zinc and taurine. Should have an osmolality permitting to be infused through central vein (> 900 mosm/L)	2	Bag
<b>ANTISEPTICS AND DISINFECTANTS</b>			
692.	Antiseptic liquid + Dichloroxylenol 2% + Terpineol 1.75% - 2% RWC 4 & 25 Litres pack	30	Bottle
693.	Aqueous formaldehyde 10% 1 litre	150	Bottle
694.	Bacillocid 0.5-2% 500 ml	70	Bottle
695.	Benzalkonium chloride 0.5% 500 ml	70	Bottle
696.	Boric acid + Chlorine (EUSOL) 5 litres	100	Bottle
697.	Cetrimide IP 15% w/v + Isopropyl alcohol 6-8% v/v + Chlorhexidine gluconate solution 7.5% v/v 1 Litre pack	30	Bottle

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

698.	Chlorhexidine gluconate 0.5% w/v + Ethanol 70% v/v hand rub 500 ml	100	Bottle
699.	Chlorhexidine gluconate (4% w/v) surgical scrub 500 ml	60	Bottle
700.	Chlorhexidine scrub 100ml	600	Bottle
701.	Chloroxyleneol 4.8% w/v 500 ml	100	Bottle
702.	Cidex dialdehyde 2.4% w/v + Glutaraldehyde solution instrument disinfectant 10 litres	10	Bottle
703.	Ethanol 70% w/v 500 ml	3700	Bottle
704.	Ethanol 95%	700	Bottle
705.	Glutaraldehyde 2% w/v 1000 ml	50	Bottle
706.	Hydrogen peroxide 3% 100ml	3300	Bottle
707.	Hydrogen peroxide 6% v/v (20 vols) IP 100 ml	100	Bottle
708.	Isopropyl alcohol 70% w/w 500 ml	70	Bottle
709.	Lysol (50% cresol with soap solution) IP 10 Litres	40	Bottle
710.	Phenol 5%	30	Bottle
711.	Phenyl 500 ml	70	Bottle
712.	Povidone iodine 5% 500 ml	150	Bottle
713.	Povidone iodine 7.5% w/v surgical scrub 500 ml	60	Bottle
714.	Povidone iodine scrub 10% 500 ml	2400	Bottle
715.	Povidone iodine 10% 500 ml	150	Bottle
716.	Sodium hypochlorite 5-6% 750 g powder	70	Pack
717.	Surgical spirit IP 5 Litres	40	Bottle
718.	Tincture benzoin compound 500 ml	100	Bottle
719.	White phenyl 20 litres	30	Bottle
720.	Low osmolar iodinated contrast agent(non-ionic monomer Iohexol/iopromide/Iopamidol minimum 350mg/ml , 100ml vial	4800	vial
721.	Low osmolar iodinated contrast agent(non-ionic monomer Iohexol/iopromide/Iopamidol minimum 350mg/ml , 50ml vial	1200	Vial
<b>Essential Narcotic Drugs</b>			
722.	Fentanyl 50 mcg 2 ml	12540	Ampoule
723.	Fentanyl 50 mcg 10 ml	6000	Vial/Ampoule
724.	Fentanyl patch 25 mcg/hr	20	Transdermal Patch
725.	Fentanyl patch 75 mcg/hr	240	Transdermal Patch
726.	Fentanyl patch 100 mcg/hr	240	Transdermal Patch
727.	Morphine 10 mg/ml 1 ml	670	Ampoule
728.	Morphine 2 mg/ml 1 ml	150	Ampoule
729.	Morphine 10 mg	1600	Tab
730.	Morphine 20 mg	500	Tab
731.	Etanercept 50mg prefilled syringe	50	Syringe
732.	Etanercept 25mg prefilled syringe	50	Syringe
733.	Isoosmolar iodinated Contrastagent(non-ionic Dimer) 320mg/ml 100ml	600	units

**\*\* The marked items will be procured from MSE firms only.**

## **I. TERMS & CONDITIONS OF E-TENDER**

1. Estimate tender value: - Rs.30 crores (approx.) (Rupees Thirty Crores Only) for Two Years.
2. **Period of contract: The Contract for supply of drugs is for twenty-four months and extendable upto one year or finalization of tender whichever is early.**
3. Earnest Money Deposit: **Rs.2,00,000/- (Rupees two lacs only)** and a non-refundable Tender Processing fee: **Rs. 600/-** (Inclusive of 18% GST) to be deposited. It may be accepted in the form of Account Payee Demand Draft, Fixed Deposit Receipt, Bankers Cheque or Bank Guarantee From any of the commercial banks or payment inline in an acceptable form.
4. Micro and Small Enterprises and Small Scale Industries are exempted for EMD as per AIIMS, Bilaspur (HP) purchase guidelines. However, there is no exemption for payment of Tender processing fee.
5. Last date of submission: Last Date for submission as per NIT.
6. Date of opening the e-tender: The fee cover of e-tender will be opened as per NIT.
7. Pre-Bid Meeting: A pre-bid meeting shall be held as mentioned in NIT (in the Procurement & Store Section, Block-D, Basement -1, AIIMS, Bilaspur (HP).

### **II. A. Eligibility Conditions of Bidders:**

1. The Tenderer must be a domestic manufacturer that is a „Class-I local supplier' or a „Class-II local supplier“ as defined under Public Procurement (Preference to Make in India), order 2017 of MoC and I (DIPP), Govt. of India, as further amended by orders of even number dated 28.05.2018, 29.05.2019, 04.06.2020 and 16.09.2020. In case the manufacturer does not quote directly, they may authorize an agent as per proforma of Manufacturer authorization form as given in the Tender enquiry document to quote and enter into a contractual obligation. **Non- local suppliers are not permitted to participate in this tender.**
2. Original Manufacturers (product under trade mark/ solely marketed/ loan license) should bear name of tender participant on the label, (i.e., name of the tender participant should be on the supplied product of drugs) only should quote their rates. Orders will be placed with the selected tender parties and payment will be made to them directly. Third party is not allowed
3. **Original Manufacturers or their Sole Authorized Distributor/Supplier having minimum average annual turnover of Rupees 120 crores and above or 10 crores and above respectively in the pervious financial years/ last 3 years (PY 2019-20,2020-21,2021-22). It should be supported with documentary evidence in the form of certified audited balance sheet of the relevant period or supported with the certificate of Chartered Accountant indicating the detail of turn over for the relevant period.**
4. Original Manufacturers or Original direct importer“s principle firm should have **at least 3 years market standing** as a manufacturer/direct importer respectively for each drug quoted in the

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

tender. Copy of the Manufacturing License/Import License renewed under Drugs and Cosmetics Act 1940 with approved list of drugs under the license should be furnished for a **period of three years up to 2023**.

5. The bidder should provide a notarized affidavit that they have not been blacklisted due to quality failure or any other issue for the quoted product /firm by any State Government/ Central Government / its Drug procurement agencies during the last 3 years.
6. The bidder has to submit Non-Conviction Certificate from State Drugs Controller stating that no case is pending against the organization under the “Drugs and Cosmetics Act and Rules” as well as under the “Drugs Price Control Order” issued from time to time.
7. Bids should not be submitted for the Drugs for which the firm /company has been blacklisted by any State Government/ Central Government / Drug procurement agencies/ due to quality failure of the drugs.
8. In compliance with order (Public Procurement No.1) No. 6/18/2019-PPD dated 23rd July 2020 issued by the Public Procurement Division, Dept. of Expenditure, Min of Finance under Rule 144(xi) of GFR 2017 any bidder from a country which shares a land border with India will be eligible to bid in this tender only if the bidder is registered with the Competent Authority.
  - a. "Bidder" (in contexts) means any person or firm or company, including any member of a consortium or joint venture (that is an association of several persons, or firms or companies), every artificial juridical person not falling in any of the descriptions of bidders stated here in before, including any agency branch or office controlled by such person, participating in a procurement process eluding the term 'bidder', 'consultant' or 'service provider' in certain
  - b. "Bidder from a country which shares a land border with India" for the purpose of this Order means: -
    - i. An entity incorporated, established or registered in such a country; or
    - ii. A subsidiary of an entity incorporated, established or registered in such a country; or
    - iii. An entity substantially controlled through entities incorporated, established or registered in such a country; or
    - iv. An entity whose beneficial owner is situated in such a country; or
    - v. An Indian (or other) agent of such an entity; or
    - vi. A natural person who is a citizen of such a country; or
    - vii. A consortium or joint venture where any member of the consortium or joint venture falls under any of the above.
  - c. The beneficial owner for the purpose of (iv) above will be as under:
    - i. In case of a company or Limited Liability Partnership, the beneficial owner is the natural person(s), who, whether acting alone or together, or through one or more juridical person, has a controlling ownership interest or who exercises control through other means.

Explanation:

      1. “Controlling ownership interest” means ownership of or entitlement to more than twenty-five per cent, of shares or capital or profits of the company;
      2. "Control" shall include the right to appoint majority of the directors or to control the management or policy decisions including by virtue of their shareholding or management rights or shareholders agreements or voting agreements;
    - ii. In case of a partnership firm, the beneficial owner is the natural person(s) who, whether



**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

- acting alone or together, or through one or more juridical person, has ownership of entitlement to more than fifteen percent of capital or profits of the partnership.
- iii. In case of an unincorporated association or body of individuals, the beneficial owner is the natural person(s), who, whether acting alone or together, or through one or more juridical person, has ownership of or entitlement to more than fifteen percent of the property or capital or profits of such association or body of individuals.
  - iv. Where no natural person is identified under (i) or (ii) or (iii) above, the beneficial owner is the relevant natural person who holds the position of senior managing official;
  - v. In case of a trust, the identification of the beneficial owner(s) shall include the identification of the author of the trust, the trustee, the beneficiaries with 15% or more interest in the trust and any other natural person exercising ultimate effective control over the trust through a chain of control or ownership.
  - d. An Agent is a person employed to do any act for another, or to represent another in dealings with third person.
  - e. In case of turnkey contracts, the successful bidder shall not be allowed to sub-contract works to any contractor from a country which shares a land border with India unless such contractor is registered with the Competent Authority.
  - f. Bidders must include a paragraph as a certificate of compliance with the above-mentioned provisions in the tender form given in the annexure.
9. Bid should not be submitted for the product(s) for which the firm / company has been blacklisted by any State Government/ Central Government/ its Drug procurement agencies due to any issue in last 3 years.

**B. Eligibility Criteria for Bidders of Renal Transplant Drugs (Tacrolimus/Mycophenolate)**

a. The company should have a market standing for Tacrolimus/Mycophenolate for a minimum of 10 years.

or

Should have experience in handling the active pharmaceutical ingredient (Tacrolimus/Mycophenolate) for a minimum period of 10 years and market standing for the formulation of Tacrolimus/Mycophenolate for a minimum of 3 years.

b. Copy of the Manufacturing License/Import License renewed under Drugs and Cosmetics Act 1940 should be furnished for a period of ten years up to 2021.

c. The manufacturer should have to submit utilization certificate for use of their brand of Tacrolimus/Mycophenolate for a period of more than one year from Head of the Department of Nephrology of a government hospital performing more than 50 kidney transplant surgeries per year.

d. All bidders are requested to quote their rate for all strengths of Tacrolimus/ Mycophenolate. Bidders not quoting rates for all the strengths will not be considered.

e. The lowest bidder will be selected by comparing the weighted cumulative rate. The weighted cumulative rate will be calculated as follows.

f. Weighted cumulative rate for Tacrolimus =  $0.21 \times (\text{rate of } 0.5 \text{ mg}) + 0.32 \times (\text{rate of } 1 \text{ mg})$

g. Weighted cumulative rate for Mycophenolate =  $0.145 \times (\text{rate of } 250 \text{ mg}) + 0.855 \times (\text{rate of } 500 \text{ mg})$

### **C. Criteria for Selecting Biologicals (Rituximab)**

1. Bidders are requested to quote for both the strength (100 mg & 500 mg) of Rituximab.
2. Selection will be based on the weighted cumulative rate calculated as mentioned below

Weighted cumulative rate for Rituximab = 0.44 X (rate of Rituximab 100 mg) + 0.56 X (rate of Rituximab 500 mg)

### **3. Firms not quoting for both the strengths will not be considered**

### **D. Purchase Preference**

- i. The Procurement of goods and services in Pharmaceuticals formulations under this e-tender will be regulated as per the applicable provisions of Public Procurement (Preference to Make in India), order (PPO) 2017 vide No. P 4502/2/2017-B.E. II dated 15/06/2017 of MoC and I (DIPP), Govt. of India, as further amended by orders of even number dated 28.05.2018,29.05.2019, 04.06.2020 and 16.09.2020. Salient portions of the order are reproduced in Appendix A of this tender document by way of information. Bidders are advised to see the original orders and satisfy themselves that they qualify to participate in the tender. Bidders who are claiming eligibility to participate in this tender must submit a certificate in format given in Appendix A along with documentary evidence in support of their claim wherever necessary failing which their bid will be summarily rejected. The minimum local content for Pharmaceutical Formulations is fixed as under:
  - a. Class-I Local supplier means a supplier or service provider, whose goods, services or works offered for procurement, has local content equal to or more than 80%.
  - b. Class-II local supplier means a supplier or service provider, whose goods, services or works offered for procurement, has local content more than 50% but less than 80%.
  - c. Non-Local supplier means a supplier or service provider, whose goods, services or works offered for procurement, has local content less than or equal to 50%.

**This tender is restricted to Class-I local suppliers and Class-II local suppliers. Non-local suppliers are not permitted to participate in this tender**

All other provisions of Public Procurement (Preference to Make in India) Order 2017, as revised by DPIIT on 16.09.2020, shall be applicable as such and shall be adhered to by bidders for procurement of any pharmaceutical formulation. The purchaser reserves the right to give preference to the „Class-I local supplier' over „Class-II local supplier“ and „Non-local supplier“ as follows:

- a. Among all qualified bidders, the lowest bid will be termed as L1. If L1 is „Class-I local supplier“, the contract for full quantity will be awarded to L1.
- b. If L1 bid is not a „Class-I local supplier“, 50% of the order shall be awarded to L1. Thereafter, the lowest bidder among the „Class-I local supplier“ will be invited to match the L1 price for the

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

- remaining 50% quantity subject to the Class-I local supplier's quoted price falling within the margin of preferences, and contract for that quantity shall be awarded to such „Class-I local supplier“ subject to matching the L1 price. In case such lowest eligible „Class-I local supplier“ fails to match the L1 price or accepts less than the offered quantity, the next higher „Class-I local supplier“ within the margin of purchase preference shall be invited to match L1 price for remaining quantity and so on and contract shall be awarded accordingly. In case, some quantity is still left uncovered on „Class-I local supplier“, then such balance will also be ordered to the L1 bidder.
- ii. The Purchaser reserves the right to give the purchase preference to small-scale sectors, Micro and small-scale enterprises etc. as per the instruction in vogue while evaluating, comparing and ranking the responsive Tenders as given in the MSMED Act 2006 reproduced below:
- a. In exercise of powers conferred in Section 11 of the Micro, Small and Medium Enterprises Development (MSMED) Act 2006, the Government has notified a new Public Procurement Policy for Micro & Small Enterprises effective from 1st April 2012. The policy mandates that 25% of procurement of annual requirement of goods and services by all Central Ministries/Public Sector Undertakings will be from the micro and small enterprises. The Government has also earmarked a sub-target of 4% procurement of goods & services from MSEs owned by SC/ST entrepreneurs out of above said 25% quantity.
- b. In accordance with the above said notification, the participating Micro and Small Enterprises (MSEs) in a tender, quoting price within the band of L1+15% would also be allowed to supply a portion of the requirement by bringing down their price to the L1 price, in a situation where L1 price is from someone other than an MSE. Such MSEs would be allowed to supply up to 25% of the total tendered value. In case there are more than one such eligible MSE, the 25% supply will be shared equally. Out of 25% of the quantity earmarked for supply from MSEs, 5% quantity is earmarked for procurement from MSEs owned by SC/ST entrepreneurs. However, in the event of failure of such MSEs to participate in the Tender process or meet the tender requirements and the L1 price, the 5% quantity earmarked for MSEs owned by SC/ST entrepreneurs will be met from other participating MSEs.
- c. The MSEs fulfilling the prescribed eligibility criteria and participating in the Tender shall enclose with their tender a copy of their valid registration certificate with District Industries Centers or Khadi and Village Industries Commission or Khadi and Village Industries Board or Coir Board or National Small Industries Corporation or any other body specified by Ministry of Micro and Small enterprises in support of their being an MSE, failing which their tender will be liable to be ignored.
- d. Special provision for Micro and Small Enterprise owned by women: – Out of the total annual procurement from Micro and Small Enterprises, 3 per cent from within the 25 per cent target shall be earmarked for procurement from Micro and Small Enterprises owned by women.
- e. Note: “If the bidder is an MSE, it shall declare in the bid document the Udyog Aadhar Memorandum Number issued to it under the MSMED Act, 2006. If a MSME bidder do not furnish the UAM Number along with bid documents, such MSE unit will not be eligible for the benefits available under Public Procurement Policy for MSEs Order 2012.

### **III. INSTRUCTIONS FOR THE BIDDERS**

1. E-Tender form shall be completed in all respect. Incomplete or e-tenders without EMD (unless eligible for exemption and proof of the same is submitted) shall be treated as invalid.
2. Bidders must ensure that all the documents are properly filled.
3. Director, AIIMS, Bilaspur (HP) reserves the right to accept or reject (fully or partially) any tender or all tender without assigning any reason.
4. Conditional tenders are liable to be rejected.
5. The EMD of unsuccessful bidders shall be refunded within one month after the award of contract to the successful bidder or in the case of successful bidder, at the end of the contract period after deducting dues from the firm if any.
- 6. The successful bidder shall have to deposit an amount 3% of the annual approximate cost as Performance Security Deposit (PSD) within two weeks after award of contract, in the form of BG, FDR or DD from any Scheduled Bank. No other mode of payment is acceptable.**
7. Bids received and found valid will be evaluated by AIIMS, Bilaspur (HP) to ascertain the completeness / correctness of the documents. The bidder should take care to submit all the information sought by AIIMS, Bilaspur (HP) in prescribed formats.
8. Incomplete bids, bids in paper format, conditional bids, telephonic bids or tenders submitted after the due date and time will not be considered and will be summarily rejected. No grounds whatsoever for late submission shall be entertained such as, but not restricted to, postal, train or flight delays, strikes or agitations of any nature etc. Vendors are, therefore, advised to submit their bids well on time.
9. Bids of eligible bidders alone will be evaluated on the basis of net rate (basic rate + GST as quoted in the financial bid) and the lowest bid (L1) will be selected except in the case of Tacrolimus, Mycophenolate and rituximab for which a separate methodology as stated in clause II B. Purchase preference as per Government of India orders will be implemented.

### **IV. SUBMISSION OF TENDERS**

1. **The bidders must ensure that they submit the soft copies of their bids within the scheduled closing date & time. No physical documents need to be submitted.**

#### **2. Late Tender:**

There is NO PROVISION of uploading late tender beyond stipulated date & time in the e-tendering system.

#### **3. Alteration and Withdrawal of Tender**

- i. The bidder, after submitting its bid, is permitted to alter/modify its bid, within the

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

deadline for submission of bids. Alterations/modifications to bids received after the prescribed deadline will not be possible on the e-tender portal.

- ii. No bid should be withdrawn after the deadline for submission of bid and before expiry of the bid validity period. If a bidder withdraws the bid during this period, it will result in forfeiture of the EMD furnished by the bidder in its bid.

**V. PREPARATION OF E-TENDERS**

**1. Documents comprising the e-Tender**

This is a Two-Bid Tender system, consisting of the **Techno-Commercial Bid and Price Bid** that are to be uploaded in the prescribed formats in the e-tendering portal.

2. The tender(s) shall only be submitted online as mentioned below:

**A. Techno-Commercial Bid shall comprise**

**i) In the “Fee” Cover**

- a. Scanned copy in pdf format of **Tender processing fee payment receipt** must be uploaded. Tender processing fee is not exempt for any bidder.
- b. Scanned copy in pdf format of **EMD receipt** or, if EMD exemption is claimed, **copy of valid registration** details proving that the bidder is a Micro or Small enterprise or is registered as a Small Scale Industry with MSME, as the case may be should be uploaded.

**ii) In the “Prequal/Technical” cover**

Scanned copy in pdf format of the following documents are to be uploaded:

- a. **Tender Form** as in Annexure 1 and **Declaration by bidder** as in Annexure 2 must be downloaded, filled in the format prescribed in the firm’s letterhead, signed in full and stamped at the appropriate places by the authorized signatory, and **manufacturer’s authorisation letter** must be scanned and uploaded as a single pdf file.
- b. **Non- Blacklisted certificate** – Notarized affidavit (as in Annexure 3), (from manufacturer), **Non- Conviction Certificate** – from State Drug Controller, must be scanned and uploaded as a single pdf file (from manufacturer) and Documentary evidence for the constitution of company Like **1. Article of Association**, (from manufacturer)
- c. Copy of **GST registration** certificate, Copy of **PAN Card** and Copy of the **Manufacturing License** renewed under Drugs and Cosmetics Act 1940. Must be scanned and uploaded as a single pdf file (from manufacturer)
- d. Copy of the **Drug license for distribution/ whole sale and retail** as per Drugs and Cosmetics Act 1940.(for Distributors and Retailers only) and **Documents for bidders of renal transplant drugs**: 1.Copy of the **Manufacturing License** renewed under Drugs and Cosmetics Act 1940 for a period of ten years up to 2021, and 2. **Utilization certificate** for use of their brand of Tacrolimus/Mycophenolate for a period of more than one year

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

from Head of the department of Nephrology of a government hospital performing more than 50 kidney transplant surgeries per year must be scanned and uploaded as a single pdf file.

- e. Bidders/original manufacturers who are claiming purchase preference under the Public Procurement (Preference to Make in India), order 2017 of MoC and I (DIPP), Govt. Of India are to upload the self-certification in the format given in **Appendix A (Mandatory)** along with the List of Products with percentage of value addition in India and address where value addition has been done, must be scanned and uploaded as a single pdf file.
- f. In case the bidder is empaneled by the Competent Authority under **GFR 144 (xi) (mandatory)** a copy of the same or **GFR 144(xi) compliance certificate** as in Annexure-4 and **Bank Details** (Beneficiary name, Bank name, Account number, IFSC code, Branch address on letterhead) must be scanned and uploaded as a single pdf file
- g. **Check list** as in annexure-5 duly filled and **A file mentioning the list of items with their make without price** for which bidder is quoting along with the applicable Make in India (MII category) status for each and signed and any other documents bidder wish to submit must be uploaded as a single PDF file.

Note:

- i) Bidders must ensure that the documents uploaded in pdf format are legible. Illegible documents will be treated as documents not submitted.
- ii) Bidder must note that the total size of all documents in any one cover, i.e. “Fee cover” and “Prequal/Technical” Cover cannot exceed more than 50 MB. Bidder must accordingly scan and upload only relevant documents scanned at appropriate resolution such as 200dpi, black and white.

**B. Price Bid:**

Prices are to be quoted in the prescribed Price Bid format provided in the e-tender portal using the BOQ template only. The price should be quoted for the **accounting unit** indicated in the e-tender document.

Note:

- i) The bidder must be diligent while filling up the Techno-Commercial Bid and Price Bid provided in prescribed formats and must not tamper with the contents of the sheets.
- ii) It is the responsibility of bidder to go through the Tender document to ensure furnishing all required documents in addition to above, if any.
- iii) ITE- Item-wise Eligibility Sheet should be downloaded, the items that the bidder wishes to quote must be selected as “Eligible”, and this “ITE file” must also be uploaded for the price bid to be considered by the system. The selected items will be displayed once uploaded and the bidder can verify that all items he wishes to quote for, are present in the list.
- iv) **The bidder can quote for one or more items mentioned in the list. Bidder has to give all details (HSN, MSE, Make-in-India, GFR 144(xi) compliance, make/brand, model,**

**pack size and remark) mentioned in BOQ for all quoted items, failure of that the bid will be rejected summarily.**

3. A person signing (manually or digitally) the tender form or any documents forming part of the contract on behalf of another shall be deemed to warrant that he has authority to do so and bind such other persons to the contract on whose behalf he is signing and if, on enquiry, it appears that the persons so signing had no authority to do so, the purchaser may, without prejudice to other civil and criminal remedies, cancel the contract and hold the signatory liable for all cost and damages.

#### **4. Digital Signing of Tender**

The bidders shall submit their tenders as per the instructions contained as above. Tenders shall be uploaded with all relevant tender documents in the prescribed format. The relevant tender documents should be uploaded by an authorized person having Class 3 digital signature certificate.

5. A bid, which does not fulfill any of the above requirements and/ or give evasive information/reply against any such requirement, shall be liable to be rejected.

6. Tender sent by fax/telex/cable shall be summarily rejected.

#### **7. Tender currencies.**

The tender shall be quoted only in INR (Indian Rupees).

#### **8. Additional information and instruction on GST:**

If the bidder desires to ask for GST, the same must be specifically indicated in the financial bid. Any other taxes or duties to be paid extra must be included by the bidder in the unit cost. In the absence of any such stipulation the price will be taken inclusive of such taxes and no claim for the same will be entertained later. The rate of GST quoted in the tender shall be taken for price comparison. However, the rate of GST quoted in the tender or the actual rate of GST applicable, whichever is lower shall be payable by the purchaser. The supplier can charge a higher GST than quoted in the tender only if the rate of GST was revised by the government after the tender closing date. **Bidders are advised to be particularly careful in filling the GST rate in the financial bid as no upward revision of GST shall be allowed unless the rate is revised by the government after bid submission date. If seller derives any benefits due to reduction/change of tax rates by the Govt., same shall be passed on to the buyer.**

#### **VI. EARNEST MONEY DEPOSIT (EMD)**

1. Pursuant to Tender terms and conditions clause 3 and 4 the tenderer shall furnish along with its tender, Earnest Money for an amount of **Rs.2,00,000/- (Rupees two lacs only)**. The Earnest Money is required to protect the purchaser against the risk of the tenderer's unwarranted conduct as amplified under sub-clause, 6 below.
2. **The tenderers who are currently registered and, also, will continue to remain registered during the tender validity period** as Micro and Small Enterprises (MSEs) as defined in

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

MSE Procurement Policy issued by Department of Micro, Small and Medium Enterprises (MSME) or with National Small Industries Corporation, shall be eligible for exemption from EMD. In case the tenderer falls in this category, it should furnish copy of its valid registration details (with MSME or NSIC, as the case maybe).

3. The earnest money shall be denominated in Indian Rupees only and paid in the form of Account Payee Demand Draft, Fixed Deposit Receipt, Bankers'Cheque or Bank Guarantee from any of the Schedule Bank on the name of Executive Director, AIIMS Bilaspur, Himachal Pradesh -174001.
4. The earnest money shall be valid for a period of forty-five (45) days beyond the validity period of the tender.
5. Unsuccessful tenderers' earnest money will be returned to them without any interest after expiry of the tender validity period, but not later than thirty days after conclusion of the resultant contract. Successful bidder's earnest money will be returned without any interest, after receipt of performance security from that tenderer.
6. Earnest Money is required to protect the purchaser against the risk of the Tenderer's conduct which would warrant the forfeiture of the EMD. Earnest money of a tenderer will be forfeited if the tenderer withdraws or amends its tender or impairs or derogates

from the tender in any respect within the period of validity of its tender or if it comes to notice that the information/documents furnished in its tender is incorrect, false, misleading or forged without prejudice to other rights of the purchaser. The successful bidder's earnest money will be forfeited without prejudice to other rights of Purchaser if it fails to furnish the required performance security within the specified period.

**VII. TENDER VALIDITY**

The contract for supply of drugs is for twenty-four months and extendable up to one year or finalization of tender whichever is earlier.

**VIII. TENDER OPENING**

1. The Tender Inviting Authority will open the e-tenders at the specified date and time and at the specified place as indicated in the NIT. In case the specified date of tender opening falls on / is subsequently declared a holiday or closed day for the Tender Inviting Authority, the tenders will be opened at the appointed time and place on the next working day.



2. Authorized representatives of the bidders, who have submitted tenders on time, may attend the tender opening provided they bring with them letters of authority from the corresponding bidders. The tender opening official(s) will prepare a list of the representatives attending the tender opening. The list will contain the representatives' names & signatures and corresponding bidders' names and addresses.
3. This being a Two-Bid Tender system, the **Techno-Commercial Tenders** are to be opened in the first instance, at the prescribed time and date as indicated in NIT. These Tenders shall be scrutinized and evaluated by the competent committee/ authority with reference to parameters prescribed in the tender document. During the Techno-Commercial Tender opening, the tender opening official(s) will read the salient features of the tenders like brief description of the goods offered, delivery period, Earnest Money Deposit and any other special features of the tenders, as deemed fit by the tender opening official(s). Thereafter, in the second stage, the Price Tenders of only the Techno - Commercially acceptable offers (as decided in the first stage) shall be opened for further scrutiny and evaluation on a date notified after the evaluation of the Techno- Commercial tender.

## **IX. SCRUTINY AND EVALUATION OF TENDERS**

### **1. Basic Principle**

Tenders will be evaluated on the basis of the terms & conditions already incorporated in the tender enquiry document, based on which tenders have been received and the terms, conditions etc. mentioned by the bidders in their tenders. No new condition will be brought in while scrutinizing and evaluating the tenders.

### **2. Scrutiny of Tenders**

- i) The Purchaser will examine the Tenders to determine whether they are complete, whether any computational errors have been made, whether required sureties have been furnished and, whether the documents uploaded are in legible form.
- ii) The Purchaser's determination of a Tender's responsiveness is to be based on the contents of the tender itself without recourse to extrinsic evidence.
- iii) The tenders will be scrutinized to determine whether they are complete and meet the essential and important requirements, conditions etc. as prescribed in the tender document. The tenders, which do not meet the basic requirements, are liable to be treated as non-responsive and will be summarily rejected.

- iv) The following are some of the important aspects, for which a tender shall be declared non-responsive during the evaluation and will be rejected;
- (i) Non-selection of Class-I local supplier or Class-II local supplier or non-local supplier in Make in India column of BOQ
  - (ii) Non-selection of GFR 144(xi) compliance column in BOQ
  - (iii) Tender validity is shorter than the required period
  - (iv) Required EMD or its exemption documents have not been provided
  - (v) Bidder has not agreed to give the required performance security of required amount in an acceptable form
  - (vi) Poor/ unsatisfactory past performance.
  - (vii) Bidders who stand de-registered/banned/blacklisted by any Central Govt. Ministries/Departments/Hospitals/Institutes
  - (viii) Bidder is not eligible as per tender conditions
  - (ix) Bidder has not quoted for the entire quantity as specified in the List of Requirements/ BOQ for the quoted
  - (x) Non-submission of all details of quoted items (HSN, MSE, Make-in-India, GFR 144(xi) compliance, make/brand, model, pack size and remark) in BOQ
  - (xi) Bidder has not agreed to other essential condition(s) specially incorporated in the tender enquiry, like delivery terms, delivery schedule, terms of payment, liquidated damages clause, warranty clause, dispute resolution mechanism applicable law.

### **3. Minor Infirmary / Irregularity/ Non-Conformity**

If during the preliminary examination, the purchaser finds any minor infirmity and/or irregularity and/or non-conformity in a tender, the purchaser may waive the same provided it does not constitute any material deviation and does not have any financial impact and, also, does not prejudice or affect the ranking order of the tenders. Wherever necessary, the purchaser will convey its observation on such „minor“ issues to the bidder

by email/registered/speed post etc. asking the bidder to respond by a specified date. If the bidder does not reply by the specified date or gives evasive reply without clarifying the point at issue in clear terms, that tender will be liable to be rejected.

### **X. AWARD OF CONTRACT:**

- a. The selection of the agency will be at the sole discretion of the AIIMS, Bilaspur (HP) who reserves its right to accept or reject any or all the proposals without assigning any reason thereof.
- b. The contract for supply of supply of Drugs, Disinfectant Fluids and Surgical Dressing Items to Department of Pharmacy, AIIMS, Bilaspur (HP), shall be awarded to the lowest responsive

bidder (basic rate + GST) for each item (i.e. L1 for each item) except as mentioned under Clause II.B above for certain special drugs for which the lowest bidder will be determined by the method stated therein.

- c. The decision on the award of contract will be intimated to the successful bidder.
- d. The annual estimate is given only as an indication. The actual quantity procured may increase or decrease. No assurance is given that the quantity stated will actually be procured.

## **XI. GENERAL CONDITIONS OF CONTRACT**

1. Only those bidders regularly maintaining enough stock and ready to supply the quoted drugs within the lead time should participate. The entire first instalment supply should be made within 45 days (55 days for narcotic drugs) from the date of issue of order and subsequent installments will be executed only on written request from the Head, Dept. of Pharmacy. The lead time for subsequent installments will be 45 days. **At a time, only one installment of supply will be accepted.**
2. Rates should be quoted as per our specification. The contract rates should include charges for door delivery of the goods at the Store Section, Block D, AIIMS, Bilaspur (HP) - 174001.
3. The prices quoted by the bidder shall not, in any case, exceed the controlled price, if any, fixed by the Govt. at the time of the supply of the articles to the Institute. If the price quoted is found to be in excess of the controlled price permissible under the Drugs (Prices Control) Order, 2013, as amended from time to time, the contractor will specifically mention this fact in his tender along with reasons for having quoted such a higher price. The Purchaser at his discretion will in such cases exercise the right of revising the price at any stage so as to conform to the controlled price or the price permissible under the Drugs Prices Control Order, 2013. This discretion will be exercised without prejudice to any other action that may be taken against the contractor.
4. Tenders should be submitted only for the drugs etc., asked for. Substitutes/Equivalents should not be offered. In case the drug asked for is not available and if rate for any of the item not quoted the column should be left blank.
5. The successful bidder may not sublet/outsourcing production of drugs quoted without the prior permission of the Director.
6. Free offers by the bidder shall not be accepted. Bidders desiring to offer free goods/items may reduce their rates suitably while quoting.
7. Prices quoted should be inclusive of all charges like packing, forwarding, Insurance, duties and education cess etc., However the breakup of GST have to be shown separately, which are or may become payable by the contractor under existing or future laws or rules of the country of origin/supply of delivery during the course of execution of the contract.
8. For any of the drugs which the successful bidder (L1) has failed to supply, it will be open to

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

the Director or to any person authorized by him on his behalf to purchase the said drug from the next lowest firm readily willing to supply or from the open market and to recover from the successful bidder (L1) the difference (Minimum Rs 5000/-), if any, between the price of the drugs so procured and the price payable under the contract to the successful bidder (L1) had the bidder supplied the drug. The minimum penalty of Rs.5,000/- shall be levied in case of non-supply even if the drug has not been procured from an alternative source.

9. Any attempt on the part of the bidders or their Agents to influence the department in their favor by personal canvassing, **allurement / undue favor / advantage** with the officers concerned will disqualify them.
10. If any product is found substandard in the terms of that product packaging and at the time of use, the whole quantity mentioned in supply order is to be replaced including consumed items without any extra cost to the hospital within 24 hours failing no payment will be made for the quantity already consumed. In addition, if replacement is not made within 24 hours, it will be open to the Director or to any person authorized by him on his behalf to purchase the said drug from the next lowest firm readily willing to supply or from the open market and to recover from the successful bidder (L1) the difference (Minimum Rs.5,000), if any, between the price of the drugs so procured and the price payable under the contract to the successful bidder (L1) had the bidder supplied the drug. The minimum penalty of Rs.5,000/- shall be levied in case the drugs are not replaced, even if the drug has not been procured from an alternative source.
11. Statutory documentation such as Sales Tax/VAT/GST etc., are the sole responsibility of the supplying agency/firm.
12. The bidder **shall** indemnify AIIMS, Bilaspur (HP) against all claims, damages or compensation under various statutory provisions, **if any liabilities are imposed against AIIMS, Bilaspur by any court / authority. The buyers shall have right to recover/ deduct the amount from performance security / bill payments or by any other legal remedy available to AIIMS.**
13. In case of breach of any terms and conditions of the contract, the Performance Security Deposit of the Contractor will be liable to be forfeited by AIIMS, BILASPUR(HP) besides annulment of the contract. This shall in no way preclude the institution's right to recover any consequential financial loss that the institution suffers, from the successful bidder from any other money due to the bidder or by any other method as available under law.
14. The rate quoted in the e-tender will be fixed for the whole contract period.
15. **The AIIMS, Bilaspur does not own any responsibility for any accident, mishappening, negligence, compensation or any act of civil or criminal nature done by supplier or his personnel engaged for the performance of this contract.**
16. **The personnel engaged by the contractor are not employee of AIIMS, Bilaspur in any manner. There is no relation of employer, principal employer, employee, agent, master and servant with the personnel/employee of contractor / supplier engaged for the performance of contracts with AIIMS. Bilaspur.**

Prices charged for supplies under rate contract by the supplier should in no event exceed the lowest

## **XII. FALL CLAUSE**

a. Prices charged for supplies under Rate Contract by the supplier should in no event exceed the lowest prices at which he bids to sell or sells the stores of identical description to any other State / Central Govt. /Autonomous Institute / Govt. Hospital / Public Undertakings during the period of the contract.

b. If at any time during the period of contract, the prices of tendered items is reduced or brought down by any law or Act of the Central or State government, the supplier shall be bound to inform Purchasing Authority immediately about such reductions in the contracted prices, in case the supplier fails to notify or fails to agree for such reductions of rates, the Purchasing authority will revise the rates on lower side. If there is a price increase for any product after quoting the rates, the bidder will have to supply the item as per quoted rates. This office will not accept any higher rates afterwards.

c. If at any time during the period of contract, the supplier quotes the sale price of such goods to any other State / Central Govt. /Autonomous Institute / Govt. Hospital / Public Undertakings at a price lower than the price chargeable under the rate contract he shall forthwith notify such reduction to Purchasing Authority and the prices payable under the rate contract for the equipment's supplied from the date of coming into force of such price stands correspondingly reduced as per above stipulation.

## **XIII. PAYMENT CLAUSE**

a. The payment would be made for actual supply taken and no claim in this regard should be entertained. 100% payment will be made on receiving goods in store conforming to approved quality and ordered quantity.

b. No payment shall be made for rejected stores. Rejected items must be removed by the supplier within two days of the date of rejection at their own cost and replace immediately. In case these are not removed, these will be auctioned at the risk and responsibility of the suppliers without notice.

c. Four copies of supplier's invoice showing contract number, goods description, quantity, unit price and total amount of with revenue stamp.

d. Two copies of packing list identifying contents of each package.

## **XIV. SPECIAL CONDITIONS**

1. Drugs should conform to the relevant Pharmacopoeial specification. The drugs should also comply with the standards required under rule 124 of the Drugs & Cosmetics Act 1935. Minimum content of active ingredients should not be less than the labeled amount at the time of delivery of drugs.

2. In case of Drugs with life:-

- a) Stock should be supplied to this Institute from the latest batch and such a stock should have a minimum life period of 18 Months. Depending upon the normal potency prescribed, supplies with a minimum life period of one year at the time of receipt will be accepted and bill will be passed only for the consumed quantity after the expiry date. Drugs less than 3 months shelf life in the stock of AIIMS, Bilaspur (HP) Pharmacy should be replaced by supplier free of cost.
  - b) In the event of such drugs not being utilized within their life period, the bidder should undertake to replace the unexpended stock by fresh stock without any extra cost.
  - c) Bidders should clearly mention the Brand name of the drugs, etc., offered by them in their bids. The composition of the formulations wherever possible may be furnished.
3. The bidder will invariably supply with Logograms as “**AIIMS, BILASPUR (HP) SUPPLY NOT FOR SALE**” along with Batch No., Manufacturing Date & Expiry Date of Drugs. Otherwise item will be rejected. Delaying supply due to Logograms will not be accepted.
  4. **Rates quoted should be on door delivery basis to the first floor of the pharmacy block. Coolie charges if any will not be borne by the institute. Coolies should be brought by the transport agencies whenever required.**
  5. **Strips, tablets & ampoules of different drugs should be visibly different in color, size and shape. If two or more drugs supplied by the bidder in this tender look similar, the supply may not be accepted. Hence, the bidders are requested to make sure the tablets/capsules/ampoules/labels do not physically resemble each other. Failure to comply will lead to cancellation of the order and alternate procurement action will be taken and the difference in cost (minimum Rs.5000/-) will be levied as penalty.**
  6. During the delivery, if it is found that the supplies do not resemble the sample carton box which were submitted and are significantly different, the supply may be rejected and the same has to be replaced within 24 hours of the supplier being intimated about it failing which the order will be placed with the next lowest firm readily willing to supply the drug or from the open market and to recover from the successful bidder (L1) the difference (Minimum Rs.5,000), if any, between the price of the drugs so procured and the price payable under the contract to the successful bidder (L1) had the bidder supplied the drug. The bidder who does not comply will be required to pay the difference in cost as penalty (minimum Rs.5,000/). The minimum penalty of Rs.5,000/- shall be levied in case the drugs are not replaced, even if the drug has not been procured from an alternative source.
  7. Bidders must quote only those items which correspond to the specifications prescribed in the tender with regard to composition, strength, packing, formulation and other aspects. However, in the absence of bidders quoting the exact specifications, the Director reserves the right to select an item that is closest to the specifications.
  8. **For Renal transplant drugs mixing the brands is not advisable. Hence, the manufacturers are instructed to quote for all drug strengths (0.5 mg and 1 mg for Tacrolimus and 250 mg and 500 mg for Mycophenolate Mofetil). Quotation for only one strength will not be considered.**

## **XV. SAMPLES**

1. Samples for Intravenous Fluids, Surgical Items and Disinfectant Items along with the carton boxes are to be submitted to the Store Section, Block D, AIIMS, Bilaspur (HP) -174001 on weekdays (Monday to Friday) between 2 P.M and 4 P.M. The messenger may request for a receipt from the person accepting the samples.
2. Samples for surgical items and disinfectant items are to be clearly labeled outside indicating the name and address of the company. A list of all the items for which samples have been sent should be enclosed in the sample package. Companies not submitting samples along with the carton boxes will not be considered and no reminder will be sent.
3. Samples must be submitted before the last date of bid.

## **XVI. SUPPLY CONDITIONS**

1. Orders will be placed with the selected tender parties and payment will be made to them directly through ECS as per Government rules.
2. **The successful bidder should intimate to this office about the supply position within one week from the date of supply order. Failing which, it would be considered that the bidder is not interested in executing the supply against the order and the purchase order will be awarded to next lowest bidder willing to supply or from the open market, at the risk and cost to the bidder.**
3. **In case the selected company wants to supply and raise the bill through their authorized distributor, the name, address and contact telephone number should be given while submitting the tender itself. Further modifications will not be entertained during the tender period. An extraordinary situation it may be permitted after the approval from the competent authority. In such case the companies are requested to supply directly from company.**
4. Each supply and batch should be accompanied with a copy of Certificate of Analysis (COA) from Government approved drugs testing laboratory/NABL accredited labs. Failure to comply may lead to rejection of supply. First supply of the item should accompany with manufacturing license/import license mentioning the name of the item supplied.
5. The strip and the package should clearly state the name of the manufacturer who has participated in the tender. Supply in loose packing is not acceptable.
6. Special drugs wherever strip packing is not available will be accepted, if provided in plastic/glass bottles.
7. The order will be awarded to the successful bidder for the supply of drugs for the specified period and the bidder shall supply on receipt of supply orders from the Officer in Charge of Purchase. A scanned copy of supply order will be sent to the e mail of the manufacturer and supplier.
8. The lead time is 45 days for General Drugs and 55 days for Narcotic Drugs.
9. **The entire first installment should be executed within 45 days (55 days for Narcotic**

**Drugs) from the date of issue of supply order. If the supply is not executed within 45 days, the supply order will be cancelled and alternate procurement action will be undertaken. The difference in cost (Minimum Rs.5000) will be recovered from the defaulted supplier as penalty.**

- 10. If part supply is ordered the supplier must execute the mentioned part supply at once. Split part supply is not accepted.**
11. All I.V. fluids unless otherwise indicated should be manufactured using Form Fill Seal (FFS) technology. The bottles should be well packed in sturdy boxes to withstand stacking and transport. If packing is not satisfactory and the cardboard boxes are flimsy, the supply will be rejected.
12. Bandages /POP bandages will be tested in the Institute and only those items which are found of good quality and suitable will be included for selection. No reason will be given for rejection.
13. Proper maintenance of the cold chain during transit is essential for drugs that require storage in cold room. Packages received without proper cool packs and whose temperature is not within stipulated range will be rejected.
14. Supply of IV-fluids should be in truck having fixed metallic roof to avoid damage during transit.
15. As far as possible supply should be made from single or minimum number of batches. Separate batches should be packed separately.
16. Packing slip containing full details about the contents like Quantity, Batch number, Manufacturing Date, and Expiry date should be pasted on every parcel.
17. Ampoules should be supplied with aluminium files for breaking them. Each pack should contain at least 5 files.
- 18. Ampoules should be supplied in boxes with 10 Ampoules to avoid damage. The boxes should be supplied with separator for each Ampoule. Similarly, vials should be packed in individual cartons.**
19. The company should ensure that the size of the letter font in the strips of the tablets, capsules and in the vials and ampoules should be clearly visible and readable to enable the Pharmacists/Doctors/Patients to identify the drugs without difficulty. Failing which the drugs will be rejected.
20. Drugs and other items supplied to the Institute should be of good quality and the decision of the Director in this regard is final and binding on the bidder. If the quality of the drugs is not satisfactory and they do not meet the requirements such as maintenance of proper cold chain, the same will be rejected and the supplied item has to be removed from the Institute by the bidder or by the contractor immediately at their own expenses after receipt of intimation. If the item is not removed within **15 days** from the date of intimation letter, the supplies will not be returned to the bidder and they will be destroyed **at the expenses of suppliers.**
- 21. The company should ensure that the drugs supplied by them should be of different strip**



**color and size. If AIIMS, Bilaspur (HP) receives any look alike drugs with same strip color and size, the supply will be rejected and alternate procurement action will be initiated. The difference in cost (Minimum Rs.5000) will be recovered from the defaulted company.**

22. Supply orders will be sent through e-mail followed with speed post. The bidders are requested to give their correct postal address and valid e mail-id to enable the delivery of supply orders. Further they are requested to check the email regularly.
23. **For serial Nos. 676 to 690 Disinfectant Fluids) and 746 to 776 (Chemicals) the supply has to accompany with MATERIAL SAFETY DATA SHEET (MSDS) containing information on physical and chemical properties of the material, potential hazards and exposure control measures, how to work safely with these materials, information on usages, storage, handling and emergency procedures relate to the hazards of the materials.**

#### **XVII. DELIVERY CONDITION**

1. The lead time will be 45 days. Hence, the delivery must be completed within 45 days from date of the supply order. The lead time will be 55 days for Narcotic items.
2. At the discretion of the Director, AIIMS, Bilaspur (HP) late delivery of a drug may be accepted after imposing a penalty at the rate of 0.2% of the Total value of the order, per day, for delayed supply subject to a maximum of 15 days for each item, beyond which it will be open to the Director or to any person authorized by him on his behalf to purchase the said drug from the next lowest firm readily willing to supply or from the open market and to recover from the successful bidder (L1) the difference (Minimum Rs.5,000), if any, between the price of the drugs so procured and the price payable under the contract to the successful bidder (L1) had the bidder supplied the drug. Acceptance of late supply after imposing a penalty is solely at the discretion of the Director, AIIMS, Bilaspur (HP) and does not confer any right on the successful bidder to supply the drug after the due date. The minimum penalty of Rs.5,000/- shall be levied in case of non-supply, even if the drug has not been procured from an alternative source.
3. Each carton should contain only ONE drug belonging to one batch only and each drug should be packed separately. Supplies with two or more drugs packed in a single pack to save space will not be accepted.
4. The drugs and other items should be properly packed to avoid damage/shortage during transit. Damages/shortages if any found on opening the case will be reported to the supplier immediately and the same should be replaced at the supplier's own cost. No insurance cost charges are payable.
5. Labeling on vials/ampoules/I.V. fluids and other items should be clear and legible. Labels should be well stuck to the container. If not, the supply may be rejected.
6. Supplies should be marked to Store Section, Block D, AIIMS, Bilaspur (HP) - 174001, and should be door delivered to the first floor of Pharmacy. Supplies sent on 'to-pay' basis will not be accepted. Coolie charges if any will not be borne by the Institute. Coolies should be brought by the transport agencies/Supplier whenever required.

### **XVIII. PACKAGING**

1. The Drugs shall be supplied in the package specification and the package shall carry the logograms specified as “**AIIMS, BILASPUR (HP) SUPPLY NOT FOR SALE**”
2. The packing in each carton shall be strictly as per the specification mentioned below. The outer carton should be of white board with a minimum of 300GSM with laminated packing for the strips, blisters, ointments, creams etc. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties.
3. No corrugated package should weigh more than 15 kgs (product + inner carton+ corrugated box). All corrugated boxes should be of „A” grade virgin paper. All drugs should be packed in firsthand boxes only.
4. The corrugated boxes should be narrow flute. Every box should be preferably single joint and not more than two joints. Every box should be stitched using pairs of metal pins with an interval of two inches between each pair. The boxes should be stitched and not joined using calico at the corners.
5. The flaps should uniformly meet but should not overlap each other. The flap when turned by 35-60 degrees should not crack. Every box should be sealed with gum tape running along the top.
6. The strength of the cardboard boxes should withstand the stacking up to 5 levels.
7. Every box should be strapped with two parallel nylon carry straps (they should intersect).
8. **The labels in the case of injections should clearly indicate whether the preparations are meant for Intravenous (IV), Intra Muscular (IM), Subcutaneous (SC), etc.**
9. It should be ensured that only first-hand fresh packaging material of uniform size including bottle and vial is used for packing.
10. All primary packing containers should be strictly conforming to the specification included in the relevant pharmacopoeia. Packing should be able to prevent damage or deterioration during transit.
11. In the event of items of drugs supplied found to be not as per specifications in respect of their packing, the Tender Inviting Authority is at liberty to make alternate purchase of the item of drugs and medicines for which the Purchase orders have been placed from any other source or in the open market or from any other bidder who might have quoted higher rates at the risk and the cost of the supplier and in such cases the tender inviting authority has every right to recover the cost and impose difference in cost as penalty.

### **XIX. OTHER CONDITIONS**

1. The Director reserves the right to reject the bids and the supply of all the items or of only one or more of the items tendered for, in a tender without assigning any reason for doing so.
2. The Director will be at liberty to terminate, without assigning any reason the Contract either wholly or in part on One Month’s Notice. The bidder will not be entitled to any compensation

whatsoever in respect of such termination. The contracts shall also be renewed for a further period beyond the contract time in cases where such renewal is necessary.

3. If any of the drugs which the successful bidder has failed to supply, it will be open to the Director or to any person authorized by him on his behalf to purchase the said articles from the next lowest bidder willing to readily supply or from any other source and to recover from the successful bidder the difference (Minimum **Rs.5000**), if any, between the price of the Drugs and the price payable under the contract to the bidder.
4. Any attempt on the part of the bidders or their Agents to influence the department in their favor by personal canvassing / **allurement / undue advantage/ favor etc.** with the officers concerned will disqualify them.
5. E mail/Hard copy quotations will not be considered.
6. **SELECTION OF TENDERS WOULD VERY MUCH DEPEND UPON THE LOWEST NET RATE (BASIC PRICE + GST). HOWEVER, PURCHASE PREFERENCE AS PER GOVERNMENT OF INDIA ORDERS WILL BE GIVEN IN CERTAIN CASES, REFER PAGE NUMBER 29 UNDER D. PURCHASE PREFERENCE.**
7. The validity of tender may be extended, if necessary at the discretion of the Director.
8. Intending bidders should submit the tender through online in prescribed form on or before the last date. Submission of Online Tender should be well in advance to avoid any problem at the eleventh hour.

## **XX. QUALITY**

1. **Drugs etc. supplied to the Institute should be of good quality and the decision of the Director in this regard is final and binding on the bidder. If the quality of drugs is not satisfactory and do not meet the Pharmacopoeial requirements or proper maintenance of cold chain, the same will be rejected and the supplied item has to be removed from the Institute by the bidder or by the supplier immediately at their own expenses after receipt of intimation. If the item is not removed within 15 days from the date of the intimation letter, the supplies will be destroyed. The drugs will not be returned to the bidder and no claim will be entertained.**
2. Each batch of supply should be accompanied with the copy of Certificate of Analysis (COA) from the Government approved drug testing laboratories as per CDSCO refer: **[www.cdsc0.nic.in/listof approved laboratories](http://www.cdsc0.nic.in/listof_approved_laboratories)**
3. **Supplies without the Certificate of Analysis from the government approved drug testing laboratories will not be accepted under any circumstances and it will be treated as rejected.**
4. If the quality of the drug is found to be not conforming to the prescribed quality level in the quality control test by Central Drugs Laboratory, Central Research Institute, Kasauli, Himachal Pradesh the supply/consignment will be rejected.
5. If any written complaints received from the user departments regarding the quality of drugs,

the whole quantity mentioned in supply order is to be replaced including consumed items without any extra cost to the hospital within 24 hours failing which no payment will be made for the quantity already consumed. In addition, if replacement is not made within 24 hours, it will be open to the Director or to any person authorized by him on his behalf to purchase the said drug from the next lowest firm readily willing to supply or from the open market and to recover from the successful bidder (L1) the difference (Minimum Rs.5,000),if any, between the price of the drugs so procured and the price payable under the contract to the successful bidder (L1) had the bidder supplied the drug. The minimum penalty of Rs 5,000/- shall be levied in case of non-supply even if the drug has not been procured from an alternative source.

6. If the quality of the drugs found to be not of standard quality, Random Samples of the batch will be tested by Central Drugs Laboratory, Central Research Institute, Kasauli, Himachal Pradesh and it will be compared with COA submitted by the company. If any deviations found, action will be taken accordingly.
7. **In case of poor quality of items supplied, the name of the bidder as well as the details of quality control failure will be displayed on the web page of AIIMS, Bilaspur (HP)**
8. **The quality issues will be intimated to CDSCO, DCGI and similar government procurement agencies.**

#### **XXI. PENALTY**

**If the successful bidder fails to supply the ordered quantity of drugs within the lead time of 45 days (55 days for narcotic drugs) from the date of issue of the order, the order will be cancelled and the alternate procurement action will be taken and the difference in cost (Minimum Rs.5000/-) will be recovered as penalty by way of adjustment against the bidder's pending bills or performance security. In addition, any shortfall will also be recovered from the successful bidder by taking recourse to such action as permitted under law. The Risk purchase penalty (difference in cost) will be recovered from L1 firm only.**

#### **XXII. FORCE MAJEURE**

1. Force Majeure (FM) means extraordinary events or circumstance beyond Human control such as an event described as an Act of God (like a natural calamity) or events such as war, strike, riots, crimes (but not including negligence or wrong-doing, predictable/seasonal rain and any other events specifically excluded in the clause). An FM clause in the contract frees **both parties from contractual liability or obligation when prevented by such events from fulfilling their obligations under the contract, which may prevent either party to discharge the obligation, the affected party shall promptly notify (i.e., within 21 days) the other party about the happening of such an event.**
2. An FM clause does not excuse a party's non-performance entirely, but only suspends it for the duration of the FM. The firm has to give notice of FM as soon as it occurs and it cannot be claimed ex-post facto. There may be a FM situation affecting the purchase organization only. In such a situation, the purchase organization is to communicate with the supplier along similar lines as above for further necessary action. If the performance in whole or in part or any obligation under this contract is prevented or delayed by any reason of FM for a period exceeding 90 (Ninety) days, either party may at its option terminate the contract without any financial repercussion on either side.

3. Notwithstanding the punitive provisions contained in the contract for delay or breach of contract, the supplier would not be liable for imposition of any such sanction so long as the delay and/or failure of the supplier in fulfilling its obligations under the contract is the result of an event covered in the FM clause.
4. Neither party shall by reason of such event be entitled to terminate the contract in respect of such performance of their obligations. The performance of any obligations under the contract shall be resumed as soon as practicable after the event has come to an end or ceased to exist. If the performance of any obligation under the contract is prevented or delayed by reason of the event beyond a period mutually agreed to, if any, or seven days, whichever is more; either party may at its option terminate the contract.
5. The Institute reserves the right to withdraw/ relax any of the terms and condition mentioned in the NIT so as to overcome any problem encountered at any stage.

### **XXIII. BLACKLISTING**

1. **If the bidder fails to supply two or more times within the stipulated period of 45 days (55 days for narcotic drugs) during the tender period, the performance security of the bidder is liable to be forfeited to the institution, in addition to the recovery of penalty involved for the above purchase.**
2. **Further, the bidder will also be liable to be blacklisted for 3 years to trade with this institute. Details of bidders blacklisted by the institute will be put up in the institute website. The same will be informed to similar government procurement agencies.**
3. **Any violation of tender norms may lead to blacklisting of the bidder by the Institute initially for one year and followed by 3 years.**

### **XXIV. REQUIREMENT OF GODOWN SPACE**

For the Drugs which will have one Truck load or more per supply, the supplier, at his own expense, should provide Godown Space outside AIIMS, BILASPUR(HP) to enable the supplies to the institute within seven days. The drugs for which the supplies will be a truck load are given below.

S. No	Nomenclature
607	Continuous ambulatory dialysis fluid 1.5% 2000 ml Bag
608	Continuous ambulatory dialysis fluid 2.5% 2000 ml Bag
697	Handloom cotton gauze absorbent 50cm x 20 mtrs with min. wt. of 250 gm packet as per schedule F(II) of Drug and cosmetics Act 1940
706	Wool cotton absorbent IP in packet of 500gm Net wt

**XXV. POINTS TO REMEMBER**

1. Listing of serial number of Drugs should follow the same serial order as in Tender Schedule.
2. Rate quoted should be for AIIMS, Bilaspur (HP).
3. Bidders should quote final rates. No discount/free goods/additives will be accepted.
4. Rates should be according to unit asked for. Specification & packing size of each product should be as per details given in the tender.
5. Plea of clerical error, typographic error etc. committed by bidder will not be accepted, unless intimated prior to opening of price bid. No correspondence will be entertained after opening the price bid.
6. The rates quoted by the bidders shall not in any case exceed the controlled Price fixed by schedule I of Drugs (Price Control Order) Amendment 2013.
7. If a bidder quotes a rate higher than the controlled rate, the bidder will be rejected and prevented from participating in the tender for the next three years.
8. The rates quoted should be in Indian currency only. Tenders in any other currency are liable to be rejected.
9. If the rate for any item is not quoted, the price column should be left blank.
10. Participation in the tender implies that the participant is accepting all terms and conditions of the tender.

**XXV. LIQUIDATED DAMAGES:**

Supplies made after the stipulated period may be accepted if required, by levying a penalty at the rate of 0.2% of the total value of the order per day, for a maximum of 15 days. However, the decision is purely on the discretion of the Director, AIIMS, Bilaspur (HP).

**XXVI. RISK CLAUSE:**

The contractor shall at all times have standby arrangements for carrying out the work under the contract, in case of any failure of the existing arrangements. AIIMS, Bilaspur (HP) reserves the right for termination of the contract at any time by giving 30 days written notice, if the services are not found unsatisfactory, and also has the right to award the contract to any other selected bidders at the cost, risk and responsibilities of contractor and excess expenditure incurred on account of this will be recovered by AIIMS, Bilaspur (HP) from the contractor's Security Deposit or pending bills or by raising a separate claim. During the notice period, the supplier shall continue the supply.

1. All necessary reports and other information will be supplied on a mutually agreed basis and regular meetings will be held with the department.
2. In the event of loss/damage of the item at the premises of the department, premises due to negligence/carelessness of contractor staff, then the contractor shall compensate the

loss to AIIMS, Bilaspur (HP).

**XXVII. TERMINATION CLAUSE:**

During the contract, AIIMS Bilaspur (HP) reserves rights to make the vendor forfeit the performance security deposit deposited with AIIMS, Bilaspur (HP) or part thereof in favor of AIIMS, Bilaspur (HP) and agreement will be terminated after giving 30 days' notice. Furthermore, in such situations, tender can be allotted to next lowest bidder readily willing to supply the item or from the open market and the difference in cost shall be recovered from the successful bidder who is in breach of the contract. In addition, in case it is found that the supplier is charging by fraudulent means or indulging in criminal activities the contract will be terminated immediately and action will be taken against the bidder as per the conditions in this tender besides other provisions of the law.

**XXVIII. ARBITRATION**

a) In the event of any dispute or differences arising as to the execution of the contract as to the respective rights or liabilities of the parties hereto or interpretation of any of clause thereof on any condition of agreement (except as to any matters the decision of which is specially provided for or the special conditions), the dispute shall be resolved in accordance with the provisions of the Arbitration & Conciliation Act, 1996 and the Rules there under and any statutory modifications thereof, for the time being in force, shall be deemed to apply to the arbitration proceedings. The award of the arbitrator shall be final and binding on parties to the agreement.

b) The arbitrator shall be appointed by the Institute.

c) The cost of arbitration shall be borne by the both parties in equal share.

d) However, during the period such disputes are settled either by mutual discussions between the parties or by legal means, the contractor shall continue to do the work as per terms & conditions of Contract.

e) In case of any dispute regarding the terms and condition of the Agreement the Notice Inviting Tender shall prevail.

f) In case of disputes, arising out of this agreement between the contractor and the Institute i.e., AIIMS Bilaspur, the Courts of Bilaspur H.P. shall have the exclusive jurisdiction.

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

**Annexure- 1**  
**TENDER FORM**  
**(On Firms' Letter Head)**

To,

Date \_\_\_\_\_

The Director  
AIIMS, BILASPUR(HP),  
174001

Ref: Your Tender Document No. \_\_\_\_\_ dated \_\_\_\_\_

We, the undersigned have examined the above-mentioned Tender document No. dated \_\_, including amendment/corrigendum No. \_\_\_\_, dated \_\_\_\_\_ (if any), the receipt of which is hereby confirmed. We now offer to supply and deliver \_\_\_\_\_ (Description of goods and services) in conformity with your above referred document **for the sum as shown in the price schedules attached herewith and made part of this tender**. If our tender is accepted, we undertake to supply the goods and perform the services as mentioned above, in accordance with the delivery schedule specified in the tender document.

We have read the clauses regarding restrictions on procurement from a bidder of a country which shares a land border with India and on sub-contracting to contractors from such countries and we certify that this bidder is not from such a country/ from such a country and has been registered with the Competent Authority and a copy of the valid registration by the Competent Authority is attached as evidence of the same (Strike out the portion not applicable). We hereby certify that this bidder fulfills all requirements in this regard and is eligible to be considered. If there are any Turnkey works involving possibility of sub-contracting the bidder will not sub-contract any work to a contractor from such countries unless such contractor is registered with the Competent Authority. I hereby certify that this bidder fulfills all requirements in this regard and is eligible to be considered.

We further confirm that, if our tender is accepted, we shall provide you with a performance security of required amount in an acceptable form in terms of Clause IV "Instructions to Bidders" Sub- Clause 6 in the tender document, for due performance of the contract.

We agree to keep our tender valid for acceptance as required in Clause VIII "Tender Validity" in the Tender document or for subsequently extended period, if any, agreed to by us. We also accordingly confirm to abide by this tender up to the aforesaid period and this tender may be accepted any time before the expiry of the aforesaid period. We further confirm that, until a formal contract is executed, this tender read with your written acceptance thereof within the aforesaid period shall constitute a binding contract between us.

We further understand that you are not bound to accept the lowest or any tender you may receive against your above-referred tender enquiry.

We confirm that we fully agree to the terms and conditions specified in above mentioned TE document, including amendment/ corrigendum if any.

(Signature with date)  
(Name and designation)



**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

Duly authorized to sign tender for and on behalf of the firm

**Annexure 2**  
**DECLARATION OF THE BIDDER**  
**(To submitted on the firm's letterhead)**

1.	Name and Address of the bidder	
2.	Name & Designation of the authorized person with signature	
3.	Phone No/ Land line number of the bidder (functional between 9 am and 5pm)	
4.	Mobile No of authorized person (available from 9am to 5pm)	
5.	Email ID of the bidder	
6.	Email ID of the authorized person	
7.	Local supplier/Distributor (complete address must be written)	
8.	Whether bidder is registered MSE Manufacturer? (If registered MSE, submit copy of the Udyog Aadhaar certificate or Equivalent Certificate)	Yes / No
If there is any change in the above details, I will immediately intimate you by speed post or email		
I ..... hereby declare that the details given above are true to the best of my knowledge and I have thoroughly read and understood the terms & conditions of the tender and shall abide by the rules.		
Signature		
Dated:		(Name with designation & seal)

**NB: This declaration form must be duly filled in by an authorized person not below the rank of Manager**

**Annexure 3**  
**Notarized affidavit**

I.....

Owner/Managing Director/Partner/Proprietor of M/s..... having its manufacturing or import unit/ registered office at ..... do hereby declare that our company/Supplied items have not been blacklisted either by any State government or Central Government Organization or its drug procurement agencies for the following products quoted in the tender during last three years. We are eligible to participate in the tender ref. No Pur.8(1)/2021/Tender I for the following products.

S. No.	Drug Code	Name of the Drug

1. I/We\_\_\_\_\_hereby submit the e-tender application for the above-mentioned items.

I/We hereby declare that I/we have perused and understood the tender document and accept all the terms and conditions, stipulated by AIIMS, BILASPUR(HP) in connection with the tender for supply of Drugs, Disinfectant Fluids and Surgical Dressing Items to Department of Pharmacy, AIIMS, BILASPUR(HP), from **September 2022 to 31<sup>st</sup> August 2025.**

2. I/we confirm that all cuttings and over-writings have been deleted and re-written afresh and initialed wherever required.

Signature of the owner/ Managing  
Partner/Director

Date:

Name:

Place:

Seal:

**N.B.:** The above declaration, duly signed by the authorized signatory of the company, should be

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

enclosed with the bid. The authorized signatory must be not below the rank of Manager

**Appendix-A**

**Self-Certification format for claiming purchase preference under the “Public Procurement Preference to Make in India” order**

As per the order issued by

(i) Department of Industrial Policy and Promotion (DIPP) vide No. P-45021/2/2017- BE-II dated 15.06.2017 as further amended by Order No. P-45021/2/2017-B.E.-II dated 28.05.2018, Order No. P- 45021/2/2017-B.E.-II dated 29.05.2019, Order No. P-45021/2/2017-PP (BE-II) dated 04.06.2020 and Order No. P-45021/2/2017-PP (BE-II) dated 16.09.2020; and

(ii) Department of Pharmaceuticals vide No. F- 31026/36/2016-MD dated 18.05.2018 and the subsequent orders thereof; the purchaser reserves the right to give preference to the local supplier.

A local supplier (definition of “local supplier” is given in clause 2 of the aforesaid order of DIPP as amended from time to time) has to submit the following along with their e-tender(s) failing which their bid will be evaluated without considering such preference mentioned in the DIPP order dated 15.06.2017 further amended on 28.05.2018, 25.09.2019 and 04.06.2020:

a. The local supplier at the time of e-tender, bidding or solicitation shall be required to provide self- certification that the item offered meets the minimum local content and shall give details of the location(s) at which the local value addition is made in the format in Annexure A.

“Certified that the following items quoted has (a) equal to or more than 80%, (b) more than 50% but less than 80%, (c) less than or equal to 50% (**Select only one**) of value addition in India at the location(s) mentioned against each and is eligible for purchase preference as per the Govt. of India “Public Procurement preference to Make in India” order Dt.15.06.2017 as further amended by Order No.P-45021/2/2017-B.E.-II dated 28.05.2018, Order No.P-45021/2/2017- B.E.-II dated 29.05.2019, and Order No. P-45021/2/2017-PP (BE-II) dated 04.06.2020.

Sl. No	Name of the item	Details of the location(s) at which the local value addition was made.

Authorized  
Signature:  
Name:

b. In cases of procurement for a value in excess of Rs. 10 Crore. the local supplier shall be required to provide a certificate from the statutory auditor or cost auditor of the company (in the case of companies) or from a practicing cost accountant or practicing chartered accountant (in respect of suppliers other than companies) giving the percentage of local content.

Minimum Local Content: „Class-I local supplier' means a supplier or service provider, whose goods, services or works offered for procurement, has local content equal to or more than 80%, as defined under the Order. “Class-II local supplier” means a supplier or service provider, whose goods, services or works offered for procurement, has local content more than 50% but less than 80%, as defined under this Order. “Non- Local supplier” means a supplier or service provider, whose goods, services or works offered for procurement, has local content less than or equal to 50%.

c. Margin of Purchase Preference: The margin of purchase preference shall be 20%.

d. Manufacture under license/technology collaboration agreements with phased indigenization are exempted from meeting the stipulated local content if the product is being manufactured in India under a license from a foreign manufacturer who holds intellectual property rights and where there is a technology collaboration agreement/transfer of technology agreement for indigenous manufacture of a product developed abroad with clear phasing of increase in local content

e. Decisions on complaints relating to implementation of this Order shall be taken by the competent authority which is empowered to look into procurement-related complaints relating the procuring entity.

f. A constituted committee with internal and external experts will examine for independent verification of self-declarations and auditor’s/accountant’s certificates on random basis and in the case of complaints.

g. In case of reference of any complaint by the concerned bidder, there would be a fee of Rs. 2 lakh or 1 % of the value of the pharmaceutical formulations being procured (subject to a maximum of Rs. 5 lakh), whichever is higher, to be paid by way of a Demand Draft to be deposited with the procuring entity, along with the complaint by the complainant. In case, the complaint is found to be incorrect, the complaint fee shall be forfeited. In case, the complaint is upheld and found to be substantially correct, deposited fee of the complainant would be refunded without any interest.

h. False declarations will be breach of the Code of Integrity under Rule 175(1)(i)(h) of the General Financial Rules for which a bidder or its successors can be debarred for up to two years as per Rule 151(iii) of the General Financial Rules along with such other actions as may be permissible under law.

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

i. A supplier who has been debarred by any procuring entity for violation of this Order shall not be eligible for preference under this Order for procurement by any other procuring entity for the duration of the debarment. The debarment for such other procuring entities shall take effect prospectively from the date on which it comes to the notice of other procurement entities.

**Annexure-4**

**GFR-144 (xi) compliance certificate**  
**(To printed on the Firm's letterhead)**

Tender No:

**GFR-144(xi) compliance certificate** (as per order F. No. 6/18/2019-PPD, Ministry of Finance, GOI)

I have read the clauses regarding restrictions under GFR 144(xi) on procurement from abidder of a country, which shares a land border with India. I certify that....., the vendor

Y is not such a country

Y is from a country and has been registered with a competent authority (attached evidence of valid registration).

(Select only one of the above and strike off the other. If the no statement is selected or both are selected, the tender is liable to be rejected)

I hereby certify that we fulfill all requirements in this regard and is eligible to be considered for the procurement on CPP portal.

Thanking you.

Authorized Signatory



**Annexure 5**

**MANUFACTURER'S AUTHORISATION FORM**

**(Letterhead)**

The Director,  
AIIMS, Bilaspur, HP

Dear Sir,

Ref: Your TE document No: \_\_\_\_\_ dated: \_\_\_\_\_

We, \_\_\_\_\_ who are proven \_\_\_\_\_ (name and description of the goods offered in the Tender) having factories at, hereby authorize Messrs. \_\_\_\_\_ (name and address of the agent) to submit a tender, process the same further and enter into a contract with you against your requirement as contained in the above referred TE documents for the above goods manufactured by us.

We also state that we are not participating directly in this tender for the following reason(s):  
\_\_\_\_\_ (Please provide reason here).

We further confirm that no supplier or firm or individual other than Messrs \_\_\_\_\_ (name and address of the above agent) is authorized to submit a tender, process the same further and enter into a contract with you against your requirement as contained in the above referred TE documents for the above goods manufactured by us. We also hereby extend our full warranty, CMC/AMC as applicable as per the General Conditions of Contract, read with modification, if any, in the Special Conditions of Contract for the goods and services offered for supply by the above firm against this TE document. We also hereby confirm that we would be responsible for the satisfactory execution of contract placed on the authorized agent.

We also confirm that the price quoted by our agent shall not exceed the price which we would have quoted directly”

Yours faithfully,

[Signature with date, name, designation and Email]

for and on behalf of Messrs \_\_\_\_\_

[Name & address of the manufacturers]

Note:

- (1) This letter of authorization should be on the letter head of the manufacturing firm and should be signed by a person competent and having the power of attorney to legally bind the manufacturer.
- (2) Original letter may be sent.
- (3) The purchaser reserves the right to verify this document with its signatory.

**All India Institute of Medical Sciences**  
**(An Institution of National Importance under Ministry of Health & Family Welfare, Government of India)**  
**Bilaspur, Himachal Pradesh**

**Annexure 6**  
**CHECK LIST**

S. No	Name of the document (All documents including this check list must be signed, stamped, scanned and uploaded)	Page No
1	i. Tender Processing Fee ( <b>Mandatory for all bidders</b> ) ii. EMD receipt or if EMD exemption, copy of valid registration.	
2	Documentary evidence for the constitution of company Like Article of Association (from manufacturer)	
3	Copy of GST registration certificate	
4	Copy of PAN card	
5	Copy of the Manufacturing License/Import License renewed under Drugs and Cosmetics Act 1940 (from manufacturer)	
6	Copy of the Drug License for distribution and to sell under Drugs and Cosmetics Act 1940	
7	<b><u>Documents for Renal Transplant Drugs</u></b> a. Market standing certificate / certificate for handling API b. Utilization certificate from the Head of the Dept.of Nephrology	
8	Non- Conviction Certificate – from State Drug Controller (from manufacturer)	
9	Tender Form (Annexure 1)	
10	Declaration of the bidder (Annexure 2)	
11	Non- Blacklisted certificate – Notarized affidavit ( <u>Annexure 3</u> ) (from manufacturer)	
12	Self-certification format for claiming purchase preference under the “ <u>Public Procurement preference to Make in India (Appendix A)</u> along with the <u>List of Products with Percentage of Local Content.</u> (from manufacturer) ( <b>Mandatory</b> )	
13	Tender signing authority issued by competent authority in favor of the person who is digitally signing/uploading the tender	
14	A copy bidder’s empanelment by the Competent Authority under GFR 144 (xi) or GFR 144 (xi) compliance certificate (Annexure-4) ( <b>Mandatory</b> )	
15	Manufacturer's Authorization form (Annexure-5)	
16	A PDF file containing list of all items quoted by the bidder with make/brand without price bid in technical cover but specifying MII Category	
17	All details of the items (HSN, MSE, Make-in-India, GFR 144 (xi) compliance, make/brand, model, pack size and remark) quoted by the bidder mentioned in BOQ.	

I/We certify that the information furnished above is true and correct. The terms and conditions are acceptable to us and have the authority to bid a tender.

Signature of the Owner/Managing  
Partner/Director

Date:  
Place:

Name:  
Seal: